> **Exported from granted.bio** · Live analysis: https://www.granted.bio/reports/53336db9-2d96-4b70-9432-d2c36f39cf60
> *This is a portable snapshot. Click through on any link to open the live analysis, follow drill-downs (projects, researchers, patents, trials), or generate your own.*

---
# Radioligand Therapy For Prostate Cancer Research Landscape

**Generated:** September 21, 2026
**Report Type:** Research Intelligence
**Data Sources:** NIH RePORTER, ClinicalTrials.gov, USPTO, PubMed


---

## How to Use This Report

NIH funding patterns validate research direction. Knowing who is funded in your space - with what methods, in what collaborations, and at what scale - calibrates where your work fits relative to the field's momentum and reveals gaps worth pursuing.

The intelligence in this report comes primarily from our semantic analysis across the linked data, not from any single source. NIH RePORTER, ClinicalTrials.gov, USPTO, and PubMed are all publicly searchable - anyone can look up individual records. Our value is in:

- Identifying conceptually-related projects via AI semantic search rather than brittle keyword matching
- Cross-linking each project to its associated patents, clinical trials, and publications
- Synthesizing across the analyzed sample to surface patterns no single record reveals - methodological trends, collaboration networks, gap analysis, and positioning signals

The Market Context section adds external color sourced via live web search. It is supplementary to the core analysis above.


---

## What This Report Does Not Cover

*A short, upfront note on the boundaries of this analysis. We surface this so you can read everything below with the right calibration.*

- **Companies are in this data - non-NIH-funded internal R&D is not.** SBIR/STTR grantees, academic-industry partnerships, and commercial entities receiving NIH funding do appear and carry real commercial weight. What's invisible is privately-funded R&D inside companies that doesn't intersect with an NIH grant.
- **International activity is largely outside the sample.** NIH RePORTER captures US grantees and their direct collaborators. Major work in Europe, China, Japan, and elsewhere is not reflected unless tied to a US-funded project.
- **Linked outputs require an NIH grant acknowledgment.** A clinical trial, patent, or publication only appears here if it was filed with an NIH project number. Industry-led trials, non-USPTO patents, and papers without NIH funding acks are missing - even when central to the field.
- **Recent quarter activity may be incomplete.** NIH RePORTER updates with a lag of several weeks; some current-fiscal-year awards may not yet be visible.
- **Umbrella institutional grants are not credited to topic funding.** Some trials and patents in this report are hosted under broad institutional support awards (P30 cancer centers, CTSA hubs, training grants) whose parent grant covers many programs beyond this topic. Those records appear in the trials and patents sections, but the host grants' dollars are deliberately excluded from Total Committed Funding to keep the headline number topically attributable. Real topic activity at those institutions is therefore likely higher than the funding figures alone suggest.
- **Market context is web-sourced**, not exhaustive - see the Sources subsection in Market Context for what was retrieved.
- **Project categorization is automated.** A single primary category is assigned per project by AI classification, with confidence scores. Some boundary cases (especially infrastructure vs. biotools) may be misassigned.

This is depth-over-breadth analysis - high signal on what NIH funds and produces, including its commercial recipients. For a complete literature view, supplement with broader PubMed/Web of Science searches and conference proceedings.
## Executive Summary

Of 115 projects totaling $105.9M across 52 organizations, the therapeutics funding category dominates at 81 projects (70.4% of 115) and $77.2M, with basic research (9 projects, 7.8%) and biotools (8 projects, 7.0%) each representing thin fractions of the sample. NIH funding was $40.9M in FY2024 and $51.2M in FY2025, though two data points do not establish a trend. The trial pipeline spans 500 trials: 74 are terminated, suspended, or withdrawn (52 terminated, 7 suspended, 15 withdrawn per the status table), and the remaining 426 are not-yet-recruiting, recruiting, active-not-recruiting, enrolling-by-invitation, completed, or otherwise active - a termination pattern worth monitoring given 61 trials have documented stop reasons. PSMA remains the dominant target anchor: Glutamate Carboxypeptidase II (PSMA) appears as a MajorTopic MeSH descriptor on 11 publications, and 357 of 500 trials carry a TREATMENT primary purpose designation.

The most concrete scientific cleavage is between beta-emitter optimization and the emerging alpha-emitter push. Within the analyzed sample, the Pb-203/212 theranostic pairing, Ac-225 combinations, and Ra-223 combination regimens each have active projects, but the alpha-emitter work remains preclinical or Phase I-stage across the NIH-funded portfolio while 177Lu-PSMA-617 (Pluvicto) has accumulated three FDA approvals and a commercial benchmark. A second cleavage sits between fixed-dosing and personalized dosimetry: multiple projects are developing deep learning and SPECT-based dosimetry tools to replace weight-based fixed dosing, an approach absent from the current commercial standard. The combination immunotherapy axis - radioligand therapy paired with checkpoint inhibitors or tumor vaccines - appears in at least five funded projects across multiple organizations, suggesting coordinated hypothesis-testing rather than isolated experiments. Within the sample, salivary gland and renal toxicity mitigation for PSMA-targeted agents represents a recurring technical focus with at least two dedicated projects.

For a researcher mapping entry points: the dosimetry personalization and alpha-emitter chelation chemistry areas show funded NIH activity but no approved clinical product, creating space for translational proposals. Three grants cluster under PA-25-301, signaling a coordinated NIH call that may support additional applications in adjacent areas. Collaboration opportunities exist at the intersection of radiopharmaceutical delivery and tumor microenvironment immunology - the RPT-resistance mechanism projects in this sample share complementary preclinical tools that are not yet integrated. The 54 DIAGNOSTIC-purpose trials alongside 6 projects in the diagnostics funding category may indicate that, within this NIH-linked sample, imaging-to-therapy theranostic work appears alongside therapeutic trial infrastructure rather than in dedicated diagnostic development programs - a pattern worth considering when designing companion imaging studies.
## What Surprised Us

*Non-obvious findings detected algorithmically from the data, then interpreted. These are **flagged hypotheses**, not verified conclusions - patterns worth investigating rather than facts to act on directly. Broader NIH ratios are directional at low topic-sample counts and could reflect real gaps OR taxonomy artifacts; treat individual findings as starting points for deeper diligence.*

**1. 5 of the top-funded PIs hold their entire NIH-linked funding on a single project with no adjacent follow-on**

A cluster of well-resourced investigators appears, within the NIH-linked sample, to be concentrated on a single project with no visible follow-on activity - a pattern that can signal either a field-defining moonshot or a fragile funding structure with no pipeline continuity if that award ends. For investors and founders mapping where durable research programs are being built, this concentration matters: $16.2M combined is meaningful capital, but if these awards conclude without successor grants, the associated research momentum may not persist in the NIH-linked record. It is worth investigating whether these investigators have parallel industry or foundation support outside NIH visibility, since the single-project appearance could reflect a classification artifact rather than a true absence of adjacent work. **Confidence: Low** - Evidence: 5 PIs among the top-funded slice, $16.2M combined on single-project awards with no adjacent NIH-linked follow-on visible in the sample.

**2. A subset of highly-funded organizations publishes actively but shows no linked patents or trials in the NIH-linked sample**

One organization in this space has accumulated 10 NIH-linked projects, $8.1M in funding, and 44 linked publications, yet shows zero linked patents and zero linked trials within the scope of this analysis - a pattern that flags a potential translation gap between discovery output and downstream clinical or commercial milestones visible through NIH acknowledgment. This matters because prolific publishing without IP or trial activity in the NIH-linked record can indicate research that is informing the field but has not crossed into protected or clinically validated territory, at least as captured here. Critically, commercial patents, international filings, and industry-sponsored trials are not captured in this sample to this dataset, so the absence of linked patents and trials should be read as a hypothesis worth investigating rather than a confirmed gap. **Confidence: Low** - Evidence: 1 organization affected, 10 combined projects, $8.1M combined NIH funding, 44 linked publications, 0 linked trials and 0 linked patents across this subgroup in the analyzed sample.



---

## Field Maturity Assessment

*Note: This assessment is based on NIH-linked clinical trials, patents, and publications. It reflects patterns in the analyzed sample and may not represent the full global research landscape.*

**Technology Readiness:** TRL 7-8

**Overall Assessment:** Established - Commercial applications exist

**Historical Reference Point:** TRL 7-8 is comparable to where immune checkpoint inhibitor therapy (anti-PD-1/PD-L1) sat roughly in 2016-2018, after FDA approvals for lead indications had been secured but with extensive ongoing trials exploring combination regimens, biomarker selection, and expansion into additional tumor types.

Based on the linked trials and publications, radioligand therapy for prostate cancer appears to be at TRL 7-8 - a field with demonstrated clinical efficacy, regulatory approvals in hand, and an extensive late-stage trial infrastructure. The sample of 500 trials includes 43 Phase 3 trials and 187 Phase 2 trials within the 378 phase-labeled trials (the phased subset of 465 interventional), alongside 646 peer-reviewed-dominant publications and NIH-linked funding of $105.9M across 115 projects, collectively pointing to a technology that has moved well beyond proof-of-concept and is operating in the realm of clinical optimization, combination strategies, and real-world deployment. A researcher entering this space now is joining a field that is refining rather than discovering - the core mechanism is validated, the competitive intensity is high, and incremental differentiation rather than platform novelty is the dominant mode of scientific work.

**Confidence: High** - Evidence: 43 Phase 3 trials, 187 Phase 2 trials, 148 Phase 1 trials across 500 total linked trials; 646 linked publications with 6% preprint ratio; $105.9M NIH-linked funding across 115 projects; 29 linked patents.

### Supporting Evidence

- **Publication Maturity:** With 646 linked publications, the 6% preprint ratio (approximately 40 preprints) is interpretable as a meaningful signal at this sample size - the low preprint share is consistent with a mature, peer-review-dominant field where findings are sufficiently established to clear editorial gatekeeping rather than requiring rapid early dissemination, though it does not rule out active emerging sub-niches within the broader topic.

**Confidence: Medium** - Evidence: 646 total linked publications, 40 preprints (~6% preprint ratio).
- **Clinical Progression:** The trial phase distribution across 500 linked trials - 148 Phase 1, 187 Phase 2, and 43 Phase 3, within 378 phase-labeled trials (the phased subset of 465 interventional) - reflects a field with substantial late-stage clinical activity; the relatively modest Phase 3 count relative to Phase 2 suggests ongoing maturation rather than full saturation, and the 138 randomized trials and 26 with double-blinded or higher masking out of 500 total reflect moderate statistical rigor, with 264 trials carrying a Data Monitoring Committee indicating broad infrastructure investment. Of 500 trials, 138 are RANDOMIZED and 26 carry DOUBLE-blinded or higher masking; 264 have an explicit Data Monitoring Committee. Statistical rigor is Medium - present at scale for randomization and DMC oversight, but blinding remains limited, which is expected given the nature of radioligand administration.

**Confidence: High** - Evidence: 500 total trials; 148 Phase 1, 187 Phase 2, 43 Phase 3 among 378 phase-labeled trials; 465 interventional, 35 observational; 138 randomized, 26 double-blinded or higher, 264 with DMC.
- **IP Activity:** The linked patent sample contains 29 patents with 0 filed in the last two years (0% recency ratio); while 29 patents is a sufficient count to note the directional signal, the zero recent filings may reflect a field where foundational IP was secured earlier and current competitive activity has shifted toward clinical and regulatory execution rather than novel IP generation, though NIH-linked patent databases may not capture all proprietary filings and this recency signal should be interpreted with caution.

**Confidence: Medium** - Evidence: 29 linked patents, 0 in last 2 years, 0% recency ratio.

### Strategic Implications

For a researcher, the density of Phase 2 activity (187 trials) relative to Phase 3 (43 trials) within 500 linked trials suggests that combination therapy regimens, patient selection biomarkers, and dosimetry optimization represent the highest-value investigator-initiated niches - these are areas where R01 and R21 mechanisms anchored in mechanistic or translational questions can complement, rather than duplicate, industry-led efficacy trials. NIH-linked funding ran from $40.9M in FY2024 to $51.2M in FY2025 in this sample, though two data points do not establish a trend, and the therapeutics category dominates within the 115 linked projects; a researcher seeking differentiation may find more proposal space in dosimetry science, resistance mechanisms, or combination sequencing rather than head-to-head efficacy, where 43 Phase 3 trials already occupy much of the evidentiary ground. Collaborator targeting should prioritize nuclear medicine physicists, radiation biologists, and biomarker-focused translational teams, given that the 26 double-blinded trials out of 500 and 138 randomized trials indicate that rigorously designed sub-studies embedded within existing platform trials may be more fundable than standalone RCTs in this competitive environment.

**Confidence: High** - Evidence: 500 total trials; 43 Phase 3, 187 Phase 2, 148 Phase 1 among 378 phase-labeled trials (phased subset of 465 interventional); 115 NIH-linked projects; $40.9M FY2024, $51.2M FY2025 (two data points only); 138 randomized, 26 double-blinded or higher.



---

## Competitive Topology

*Note: Key players listed below are derived from NIH-funded project data and represent academic/research institutions. Commercial entities may not appear. The 5 clusters below are the methodological groupings the synthesis identified as most distinct in the analyzed abstracts - clusters are cross-cutting (a single project can belong to more than one), and a different cut of the data could resolve at 3 or 6 clusters rather than 5.*

Among the funded projects in this NIH-linked sample, the competitive topology is organized around a mature PSMA-targeted RLT core (approximately 18 projects) that is being extended in three simultaneous directions: (1) radionuclide physics improvements via alpha-emitter theranostic pairing (approximately 12 projects), (2) biological response amplification via immune combination strategies (approximately 10 projects), and (3) dosimetry-driven precision via computational and AI planning tools (approximately 5 projects). These clusters are not mutually exclusive - several projects combine alpha emitters with theranostic imaging or pair PSMA targeting with immunotherapy - creating a topology where the PSMA core acts as a shared platform and the surrounding clusters compete for the next layer of clinical differentiation.

**Confidence: High** - Evidence: 45-plus relevant projects analyzed across the full 115-project list, with multi-source corroboration from 15 patents, 10 clinical trials, and funding concentration data across 10 leading organizations.

### Methodological Clusters

| # | Approach | Key Players | Maturity | Commercial Readiness |
|---|----------|-------------|----------|---------------------|
| 1 | **PSMA-Targeted Radioligand Therapy with Radionuclide and Ligand Engineering** | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SLOAN-KETTERING INST CAN RESEARCH, JOHNS HOPKINS UNIVERSITY, DIVISION OF BASIC SCIENCES - NCI, ... | Mature | This is the most translationally advanced cluster in the sample, anchored by FDA-approved 177Lu-PSMA-617 (Pluvicto) as a clinical reference point, with active Phase 1 dose-escalation trials at multiple sites and a dense patent portfolio covering PSMA chelation chemistry and ligand scaffolds (15 patents identified, predominantly from JOHNS HOPKINS UNIVERSITY); near-term commercial activity centers on reducing off-target toxicity (salivary gland, renal) and on next-generation ligand variants. |

**Confidence: High** - Evidence: approximately 18 projects across UCSF, MSK, Johns Hopkins, U Michigan, Fred Hutchinson, NCI, and two commercial entities (TRIPILL BIOTECHNOLOGY and CANCER TARGETED TECHNOLOGY), corroborated by 4 clinical trials (Phase 1 Lu-177-PSMA dose escalation, SPECT dosimetry trials) and 12 PSMA-specific patents.

---

| # | Approach | Key Players | Maturity | Commercial Readiness |
|---|----------|-------------|----------|---------------------|
| 2 | **Alpha-Particle Emitter Radiopharmaceutical Therapy with Theranostic Pairing** | SLOAN-KETTERING INST CAN RESEARCH, UNIVERSITY OF IOWA, WASHINGTON UNIVERSITY, JOHNS HOPKINS UNIVERSITY, ... | Emerging | Alpha-emitter theranostic pairing (notably Pb-203/Pb-212, Ac-225, Ra-223, and Bi-213 platforms) is progressing from preclinical optimization toward early clinical translation, with one Early Phase 1 trial (212Pb-Pentixather) identified in the sample and active chelation chemistry development; commercial readiness is limited by isotope supply chain constraints and the absence of approved alpha-emitter agents for prostate cancer beyond Ra-223, though the Pb-203/212 theranostic pair shows the clearest near-term translational trajectory. |

**Confidence: High** - Evidence: approximately 12 projects across MSK, U Iowa, Washington U, Johns Hopkins, UCSB, SUNY Stony Brook, Cornell, U Pittsburgh, and QSCINT IMAGING SOLUTIONS, corroborated by 1 early-phase clinical trial and isotope-specific chelator patents.

---

| # | Approach | Key Players | Maturity | Commercial Readiness |
|---|----------|-------------|----------|---------------------|
| 3 | **Dosimetry-Guided Personalization and AI-Based Treatment Planning for Radiopharmaceutical Therapy** | UNIVERSITY OF MICHIGAN AT ANN ARBOR, YALE UNIVERSITY, JOHNS HOPKINS UNIVERSITY, DIVISION OF BASIC SCIENCES - NCI | Emerging | Computational dosimetry and deep learning treatment planning for RPT represent an active but relatively narrow segment of the sample, with clinical-stage SPECT/CT dosimetry protocols running at UNIVERSITY OF MICHIGAN and JOHNS HOPKINS and Yale's deep learning PSMA dosimetry project targeting clinical workflow integration; commercialization pathways likely involve software-as-medical-device regulatory classification, and no dedicated commercial entities appear within the NIH-linked sample for this approach. |

**Confidence: Medium** - Evidence: 4-5 projects concentrated across U Michigan, Yale, and Johns Hopkins, corroborated by 2 clinical trials explicitly focused on dosimetry optimization (SPECT imaging for dosimetry, SPECT/CT for Lu-177-PSMA-617 therapy).

---

| # | Approach | Key Players | Maturity | Commercial Readiness |
|---|----------|-------------|----------|---------------------|
| 4 | **Radioligand Therapy Combined with Immune Modulation and Checkpoint Blockade** | UNIVERSITY OF WISCONSIN-MADISON, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, UNIVERSITY OF CALIFORNIA LOS ANGELES, UNIVERSITY OF COLORADO DENVER, ... | Emerging | Combinations of targeted radionuclide therapy with tumor vaccination, checkpoint inhibitors, or CAR-T cell priming represent one of the fastest-growing strategic directions in the sample, with multiple projects explicitly mechanistically investigating immunogenic cell death, T-cell expansion, and microenvironment reprogramming after RPT; a Phase 1 trial of Y-NM600 with anti-PD-1/PD-L1 at UNIVERSITY OF WISCONSIN is the primary clinical signal, and commercialization timelines are likely 5-8 years given the mechanistic complexity and need for combination IND strategies. |

**Confidence: High** - Evidence: approximately 10 projects across UW-Madison, UCSF, UCLA, U Colorado Denver, and NCI, corroborated by 2 patents (TARGETED RADIOTHERAPY CHELATES FOR IN SITU IMMUNE MODULATED CANCER VACCINATION from U Wisconsin) and 1 active Phase 1 immuno-RPT combination trial.

---

| # | Approach | Key Players | Maturity | Commercial Readiness |
|---|----------|-------------|----------|---------------------|
| 5 | **Novel Targeting Vector and Chelator Chemistry for Expanded Antigen Scope** | SLOAN-KETTERING INST CAN RESEARCH, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, ILLINOIS INSTITUTE OF TECHNOLOGY, CORNELL UNIVERSITY, ... | Nascent | Projects developing new targeting vectors beyond PSMA (including DLL3-antibody conjugates, CD46-directed agents, TGF-beta theranostics, neurotensin receptor-1 agents, Meitner-Auger PARP1 ligands, and next-generation chelator scaffolds for Lu-177, Y-90, and alpha emitters) represent the most heterogeneous and early-stage cluster in the sample; commercial readiness is low for most constituents given that the majority are preclinical, though MOLECULAR TARGETING TECHNOLOGIES holds an active project targeting lung cancer with Lu-177 EBRGD and a few antibody-chelator conjugate platforms are approaching IND-enabling studies. |

**Confidence: Medium** - Evidence: approximately 8-10 projects spanning MSK, UCSF, Illinois Tech, Cornell, UW-Madison, Molecular Targeting Technologies, Washington U, and UT Southwestern, with limited patent or trial corroboration for the specific novel-vector subcomponents; confidence is medium due to project count and multi-org spread but absence of cross-source validation for most individual vectors.

### Strategic Implications

For a researcher considering where to position a new program, the PSMA-targeted RLT cluster carries the highest competition density in this sample and the most crowded grant landscape (R01 applications here face well-resourced incumbents with established clinical pipelines); differentiation opportunities favor dosimetry-guided personalization and AI treatment planning, where the sample shows only 4-5 active projects and a clinical need is already validated by running SPECT dosimetry trials but no dominant methodological standard has emerged - an R01 or R21 framing around prospective dosimetry-response modeling could find meaningful white space. The immunomodulatory combination approach (RPT plus checkpoint or vaccine) is scientifically distinctive and mechanistically rich, making it well-suited for P01 or U54 program project mechanisms that can support the multi-investigator complexity these combinations require, but the field is rapidly filling and mechanistic novelty of the specific immune axis will be the primary differentiator in peer review. The novel targeting vector and chelator chemistry cluster carries the most scientific risk but also the least crowded grant environment within this sample, making early-stage R21 mechanisms or SBIR/STTR partnerships (particularly for chelator or isotope supply innovations) a reasonable positioning for labs with synthetic chemistry or radiochemistry core competencies.

**Confidence: Medium** - Evidence: cluster sizing based on 45-plus projects in the NIH sample; dosimetry cluster rests on 4-5 projects and 2 clinical trials; immunocombination cluster on approximately 10 projects and 1 active Phase 1 trial; novel vector cluster on 8-10 projects with limited clinical corroboration.



---

## Industry Engagement

Of 500 clinical trials in this landscape:

- **4 (1%)** industry-lead (lead sponsor class INDUSTRY on ClinicalTrials.gov)
- **38 (8%)** academic- or NIH-led with an industry collaborator
- **458 (92%)** academic / NIH only (no industry sponsor or collaborator)

**Industry-lead sponsors on this topic:** Alessa Therapeutics Inc., AIQ Solutions, Roll International Corporation, Candel Therapeutics, Inc.

**Industry collaborators on academic-led trials:** Bristol-Myers Squibb (4), Merck Sharp & Dohme LLC (3), Viewray Inc. (2), Novartis (2), Perspective Therapeutics (2), Blue Earth Diagnostics (2), Aventis Pharmaceuticals (2), Genentech, Inc. (2)

**Signal:** Industry engagement is limited (8% of trials). The commercial pipeline for this topic is early or the field is not yet BD-active.

*Method: sponsor and collaborator classes are source-truth from ClinicalTrials.gov (protocolSection.sponsorCollaboratorsModule.leadSponsor.class and collaborators[].class). Coverage varies by trial vintage - some older trials predate CT.gov's sponsor classification and are counted as "no data" rather than "not engaged".*

---

## White Space Analysis

*This section maps what NIH-funded research covers vs. what's underrepresented within the topic scope. Private R&D, international research, and non-NIH federal funding (DoD, DARPA, industry) are not captured here. Broader-NIH counts are filtered to radioligand therapy for prostate cancer scope so comparisons are topically apples-to-apples. **Sample counts** match against title AND abstract for the analyzed project set; **broader-NIH counts** match against title ONLY (abstracts aren't full-text-indexed at query time), so broader counts are directional lower bounds.*

> **Base rate for "Broader NIH" columns:** every broader-NIH cell below is drawn from **1,198 NIH projects** matching the radioligand therapy for prostate cancer scope filter - not the full ~154K RePORTER universe. Read broader-NIH counts as shares of that 1,198-project scope, not of all NIH funding.

> **How to read this section.** Each of the 5 dimensions below is a different axis (e.g., Production Platform, Therapeutic Target). For each project we check whether its title or abstract mentions any keyword in any of that dimension's categories. If yes, the project is *matched* on that axis. If no, it's *unclassified* on that axis - usually because the project doesn't foreground that particular axis (a "cell-free antibody discovery for HIV" project foregrounds Engineering and Therapeutic Target but rarely names a specific Antibody Format, so it lands unclassified on Format). **A project can be matched on some axes and unclassified on others.** High unclassified rates on an axis typically mean the sample doesn't foreground that axis - not that the projects are broken or the taxonomy is wrong.

### Overview

Across the 115 NIH-funded projects ($105.9M) analyzed for radioligand therapy in prostate cancer, coverage is heavily concentrated in a few well-established nodes: PSMA as the dominant molecular target (29 of 115 projects, 25.2%), Lutetium-177 as the preferred radionuclide (22 of 115, 19.1%), monotherapy optimization as the leading therapeutic strategy (34 of 115, 29.6%), and ligand/radiopharmaceutical design as the top translational focus (33 of 115, 28.7%). Coverage thins substantially in combination therapeutic strategies, alternative radionuclides beyond Lu-177 and Ac-225, and several disease-context sub-populations. These findings reflect NIH RePORTER-indexed federal funding - the largest publicly searchable source of non-dilutive US biomedical grants - but exclude private industry, international programs, and non-NIH federal investment, so the full R&D picture is broader than what is captured here. Notably, one disease subtype, metastatic castration-resistant prostate cancer, is absent from this sample despite substantial broader NIH activity; because this rests on a zero sample count, it should be treated as a directional signal rather than a confirmed gap.

**Confidence: High** - Evidence: 115 projects across 5 dimensions, 96.5% on-topic sample, deterministic coverage counts from titles and abstracts.

### Coverage by Molecular Target / Antigen

*The primary molecular target or antigen that the radioligand or radiopharmaceutical is designed to bind*

<!-- chart:white-space-dimension:0 -->

| Category | Projects | % of Sample | Funding | Broader NIH (radioligand therapy for prostate cancer) |
|----------|---------:|------------:|--------:|------------:|
| PSMA | 29 | 25.2% | $24.3M | 39 [†] |
| Androgen Receptor / Androgen Signaling | 5 | 4.3% | $3.8M | 53 [†] |
| CD46 | 1 | 0.9% | $2.0M | 3 |
| DLL3 / Neuroendocrine Markers | 4 | 3.5% | $3.1M | 6 |
| TGF-beta / Tumor Microenvironment Ligands | 1 | 0.9% | $1.3M | 4 |
| HER2 / Growth Factor Receptors | 1 | 0.9% | $2.2M | 2 |
| STEAP / Cell-Surface Prostate Antigens | 1 | 0.9% | $1.3M | 0 |
| Integrin / Extracellular Matrix Targets | 1 | 0.9% | $1.2M | 3 |
| Gold Nanoparticle / Nanoparticle-Conjugated Targets | 0 | 0.0% | $0.0M | 1 |
| Multi-Target / Bispecific Ligand Approaches | 1 | 0.9% | $1.4M | 0 |

> [†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

*Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 72 classified projects.*

*Keywords per category (what was counted):*

- **PSMA**: `psma`, `prostate-specific membrane antigen`, `psma-targeted`, `psma ligand`, `psma radioligand`, `psma-617`, `psma inhibitor`, `glutamate carboxypeptidase ii`, `gcpii`
- **Androgen Receptor / Androgen Signaling**: `androgen receptor`, `androgen signaling`, `ar-targeted`, `non-steroidal androgen`, `ar nuclear localization`, `androgen deprivation`, `enzalutamide`, `abiraterone`, `ar radioligand`
- **CD46**: `cd46`, `membrane cofactor protein`, `cd46-directed`, `cd46 radioligand`, `cd46 targeted therapy`
- **DLL3 / Neuroendocrine Markers**: `dll3`, `delta-like ligand 3`, `neuroendocrine marker`, `sstr`, `somatostatin receptor`, `peptide receptor`, `neuroendocrine carcinoma`, `grpr`, `gastrin-releasing peptide receptor`
- **TGF-beta / Tumor Microenvironment Ligands**: `tgf-beta`, `tgfβ`, `transforming growth factor beta`, `tumor microenvironment target`, `tme ligand`, `stromal target`, `fibroblast activation protein`, `fap`
- **HER2 / Growth Factor Receptors**: `her2`, `egfr`, `epidermal growth factor receptor`, `her2-targeted radionuclide`, `growth factor receptor radioligand`, `fgfr`
- **STEAP / Cell-Surface Prostate Antigens**: `steap`, `six-transmembrane epithelial antigen`, `prostate stem cell antigen`, `psca`, `cell-surface prostate antigen`, `prostate-specific antigen target`
- **Integrin / Extracellular Matrix Targets**: `integrin`, `rgd peptide`, `extracellular matrix target`, `fibronectin`, `vitronectin receptor`, `alphavbeta3`, `integrin-targeted radioligand`
- **Gold Nanoparticle / Nanoparticle-Conjugated Targets**: `gold nanoparticle`, `aunp`, `nanoparticle-conjugated`, `nanoparticle targeted`, `psma-targeted aunp`, `nanoparticle radiosensitizer`
- **Multi-Target / Bispecific Ligand Approaches**: `bispecific ligand`, `dual-target radioligand`, `multi-target radionuclide`, `bispecific radioimmuno`, `multi-antigen targeting`, `tandem ligand`

In the Molecular Target / Antigen dimension, coverage is sharply concentrated around PSMA, which appears in 29 of 115 projects (25.2% of sample) - more than any other individual target and roughly 6x the next largest classified target, androgen receptor/androgen signaling at 5 projects (4.3%). The remaining named targets - CD46, DLL3/neuroendocrine markers, TGF-beta, HER2, STEAP, integrin/ECM targets, and multi-target/bispecific approaches - each appear in 0 to 4 projects, collectively reflecting thin but distributed interest in non-PSMA antigen space. Forty-three of 115 projects are unclassified in this dimension, suggesting a portion of the sample addresses targeting concepts not easily mapped to a single antigen category.

**Confidence: High** - Evidence: 72 of 115 projects matched; PSMA at 29 projects (25.2%) is the dominant category; next-largest is AR/androgen signaling at 5 projects (4.3%).

### Coverage by Radionuclide / Emission Type

*The specific radionuclide or type of radioactive emission used in the therapy or theranostic approach*

<!-- chart:white-space-dimension:1 -->

| Category | Projects | % of Sample | Funding | Broader NIH (radioligand therapy for prostate cancer) |
|----------|---------:|------------:|--------:|------------:|
| Lutetium-177 (Beta Emitter) | 22 | 19.1% | $16.8M | 3 |
| Actinium-225 (Alpha Emitter) | 9 | 7.8% | $12.0M | 0 |
| Radium-223 (Alpha Emitter) | 1 | 0.9% | $0.4M | 1 |
| Lead-212 / Lead-203 Theranostic Pair | 4 | 3.5% | $2.4M | 2 |
| Bismuth-213 / Bismuth-212 (Alpha Emitter) | 0 | 0.0% | $0.0M | 0 |
| Iodine-131 / Iodine-125 (Beta/Auger Emitter) | 1 | 0.9% | $0.9M | 0 |
| Yttrium-90 (Beta Emitter) | 0 | 0.0% | $0.0M | 1 |
| Copper-64 / Copper-67 (Theranostic Pair) | 1 | 0.9% | $1.2M | 0 |
| Terbium Isotopes (Multi-Modal Theranostic) | 1 | 0.9% | $0.4M | 0 |
| Novel / Emerging Radionuclides | 1 | 0.9% | $0.6M | 0 |

*Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 44 classified projects.*

*Keywords per category (what was counted):*

- **Lutetium-177 (Beta Emitter)**: `lutetium-177`, `lu-177`, `177lu`, `lutetium therapy`, `beta emitter therapy`, `lu-psma`, `177lu-psma`, `lutetium radioligand`
- **Actinium-225 (Alpha Emitter)**: `actinium-225`, `ac-225`, `225ac`, `actinium alpha therapy`, `actinium psma`, `225ac-psma`, `alpha-particle actinium`
- **Radium-223 (Alpha Emitter)**: `radium-223`, `ra-223`, `223ra`, `radium dichloride`, `xofigo`, `radium combination therapy`, `radium alpha emitter`
- **Lead-212 / Lead-203 Theranostic Pair**: `lead-212`, `pb-212`, `212pb`, `lead-203`, `pb-203`, `203pb`, `lead theranostic`, `pb-212 alpha therapy`, `lead-212 psma`
- **Bismuth-213 / Bismuth-212 (Alpha Emitter)**: `bismuth-213`, `bi-213`, `213bi`, `bismuth-212`, `bi-212`, `bismuth alpha emitter`, `bismuth targeted therapy`
- **Iodine-131 / Iodine-125 (Beta/Auger Emitter)**: `iodine-131`, `i-131`, `131i`, `iodine-125`, `i-125`, `125i`, `radioiodine therapy`, `iodine radiolabeled`
- **Yttrium-90 (Beta Emitter)**: `yttrium-90`, `y-90`, `90y`, `yttrium beta emitter`, `yttrium radiolabeled`, `y-90 radiotherapy`
- **Copper-64 / Copper-67 (Theranostic Pair)**: `copper-64`, `cu-64`, `64cu`, `copper-67`, `cu-67`, `67cu`, `copper theranostic`, `copper radionuclide therapy`
- **Terbium Isotopes (Multi-Modal Theranostic)**: `terbium-149`, `terbium-161`, `tb-149`, `tb-161`, `terbium alpha emitter`, `terbium theranostic`, `terbium radionuclide`
- **Novel / Emerging Radionuclides**: `astatine-211`, `at-211`, `211at`, `rhenium-188`, `scandium-47`, `samarium-153`, `holmium-166`, `emerging radionuclide`, `novel isotope therapy`

The Radionuclide / Emission Type dimension has the highest unclassified rate of all five dimensions - 71 of 115 projects (61.7%) - indicating that a majority of projects in this sample do not foreground a specific isotope in their title or abstract. Among the 44 classified projects, Lutetium-177 dominates at 22 projects (19.1% of sample), followed by Actinium-225 at 9 projects (7.8%), reflecting the field's clinical and preclinical investment in these two isotopes. The Lead-212/Lead-203 theranostic pair appears in 4 projects (3.5%), while Bismuth-212/213, Yttrium-90, and several novel/emerging radionuclides each appear in 0 or 1 projects - counts too sparse to draw coverage conclusions beyond noting they are minimally represented in this sample.

**Confidence: Medium** - Evidence: 44 of 115 projects matched; Lu-177 at 22 projects (19.1%), Ac-225 at 9 projects (7.8%); 71 unclassified projects limit interpretability.

### Coverage by Therapeutic Strategy / Combination Approach

*The overarching treatment strategy or combination regimen in which radioligand therapy is deployed*

<!-- chart:white-space-dimension:2 -->

| Category | Projects | % of Sample | Funding | Broader NIH (radioligand therapy for prostate cancer) |
|----------|---------:|------------:|--------:|------------:|
| Radioligand Therapy Monotherapy Optimization | 34 | 29.6% | $29.8M | 49 [†] |
| Combination Radioligand Therapy (RLT + RLT) | 1 | 0.9% | $0.3M | 2 |
| Radioligand + External Beam Radiotherapy | 3 | 2.6% | $2.1M | 6 |
| Radioimmunotherapy / Radioligand + Immunotherapy | 2 | 1.7% | $1.5M | 3 |
| Radioligand + Vaccine / Antigen-Specific Immunization | 3 | 2.6% | $3.4M | 0 |
| Radioligand + Antibody Drug Conjugate (ADC) | 2 | 1.7% | $0.8M | 3 |
| Radioligand + Targeted Small Molecule Therapy | 1 | 0.9% | $1.0M | 0 |
| Radiosensitization Strategies | 5 | 4.3% | $3.7M | 5 |
| Theranostic Paired Imaging and Therapy | 21 | 18.3% | $18.6M | 64 [†] |
| PSMA Expression Modulation to Enhance Therapy | 3 | 2.6% | $2.7M | 2 |

> [†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

*Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 76 classified projects.*

*Keywords per category (what was counted):*

- **Radioligand Therapy Monotherapy Optimization**: `radioligand therapy`, `radioligand therapies`, `targeted radionuclide therapy`, `radiopharmaceutical therapy`, `molecular radiotherapy`, `rpt monotherapy`, `radioligand optimization`, `psma radioligand monotherapy`
- **Combination Radioligand Therapy (RLT + RLT)**: `combination radioligand therapy`, `dual radioligand`, `tandem radionuclide therapy`, `combination rpt`, `multi-radioligand`, `radioligand combination regimen`
- **Radioligand + External Beam Radiotherapy**: `external beam radiotherapy`, `ebrt combination`, `radioligand ebrt`, `combined radiotherapy`, `radiopharmaceutical ebrt`, `radiosensitizer external beam`, `psma radiosensitizer`, `sbrt combination`
- **Radioimmunotherapy / Radioligand + Immunotherapy**: `radioimmunotherapy`, `radioligand immunotherapy`, `checkpoint inhibitor combination`, `anti-pd1 radionuclide`, `anti-pdl1 radiopharmaceutical`, `immune checkpoint radioligand`, `t-cell activation radionuclide`, `immunoradiotherapy`
- **Radioligand + Vaccine / Antigen-Specific Immunization**: `antigen-specific vaccine`, `tumor vaccine radionuclide`, `cancer vaccine radiopharmaceutical`, `vaccination radiopharmaceutical therapy`, `t-cell vaccine combination`, `vaccine rpt`, `immunization radioligand`
- **Radioligand + Antibody Drug Conjugate (ADC)**: `antibody drug conjugate`, `adc combination`, `radioimmuno adc`, `radioligand adc`, `combined adc radiopharmaceutical`, `antibody chelator conjugate`, `immunoconjugate radionuclide`
- **Radioligand + Targeted Small Molecule Therapy**: `parp inhibitor combination`, `olaparib radioligand`, `small molecule combination rpt`, `targeted therapy radioligand`, `kinase inhibitor radionuclide`, `androgen receptor inhibitor combination`
- **Radiosensitization Strategies**: `radiosensitizer`, `radiosensitization`, `psma radiosensitizer`, `radiopharmaceutical sensitization`, `therapeutic index radiosensitizer`, `radiosensitizing agent prostate`, `dna damage radiosensitizer`
- **Theranostic Paired Imaging and Therapy**: `theranostic`, `theranostics`, `image-guided therapy`, `diagnostic-therapeutic pair`, `companion diagnostic radioligand`, `theranostic psma`, `imaging therapy pairing`, `matched pair radionuclide`
- **PSMA Expression Modulation to Enhance Therapy**: `psma expression modulation`, `psma upregulation`, `psma downregulation`, `lutetium therapy modulation`, `melt`, `psma expression enhancement`, `epigenetic psma regulation`, `androgen receptor psma`

In the Therapeutic Strategy / Combination Approach dimension, radioligand therapy monotherapy optimization is the dominant category at 34 projects (29.6% of sample), and theranostic paired imaging and therapy is a substantial secondary cluster at 21 projects (18.3%) - each cited separately as they are non-exclusive rows. Combination strategies such as RLT + immunotherapy (2 projects, 1.7%), RLT + external beam radiotherapy (3 projects, 2.6%), RLT + vaccine approaches (3 projects, 2.6%), RLT + ADC (2 projects, 1.7%), and radiosensitization (5 projects, 4.3%) are each present but thinly represented relative to the monotherapy and theranostic clusters. The broader NIH count for theranostic paired imaging (64) is notably elevated relative to peer categories in this dimension - this count likely reflects the term's prevalence across cancer imaging broadly and should be treated as directional rather than topic-specific.

**Confidence: High** - Evidence: 76 of 115 projects matched; monotherapy at 34 projects (29.6%), theranostics at 21 projects (18.3%); combination strategy rows each at 5 projects or fewer.

### Coverage by Cancer Type / Disease Context

*The primary cancer type or disease context in which the radioligand or radiopharmaceutical approach is being studied*

<!-- chart:white-space-dimension:3 -->

| Category | Projects | % of Sample | Funding | Broader NIH (radioligand therapy for prostate cancer) |
|----------|---------:|------------:|--------:|------------:|
| Prostate Cancer (Hormone-Sensitive) | 16 | 13.9% | $10.8M | 0 |
| Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 0 | 0.0% | $0.0M | 65 [†] |
| Neuroendocrine Prostate Cancer | 3 | 2.6% | $3.7M | 31 [†] |
| Neuroendocrine Tumors (Non-Prostate) | 2 | 1.7% | $0.4M | 6 |
| Lung Cancer / High-Grade Neuroendocrine Lung | 4 | 3.5% | $3.6M | 4 |
| Liver / Hepatocellular Cancer | 2 | 1.7% | $1.9M | 1 |
| Breast Cancer | 1 | 0.9% | $0.6M | 7 |
| Colorectal Cancer | 2 | 1.7% | $1.4M | 1 |
| Pancreatic Cancer | 3 | 2.6% | $3.0M | 0 |
| Bone Metastases / Skeletal Involvement | 3 | 2.6% | $2.8M | 6 |
| Renal / Bladder / Urologic Cancers (Non-Prostate) | 2 | 1.7% | $0.9M | 0 |

> [†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

*Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 63 classified projects.*

*Keywords per category (what was counted):*

- **Prostate Cancer (Hormone-Sensitive)**: `hormone-sensitive prostate cancer`, `hspc`, `castration-sensitive prostate`, `androgen-sensitive prostate`, `non-metastatic prostate`, `biochemically recurrent prostate`, `prostate cancer biochemical recurrence`
- **Metastatic Castration-Resistant Prostate Cancer (mCRPC)**: `metastatic castration-resistant prostate cancer`, `mcrpc`, `castration-resistant prostate`, `crpc`, `hormone-refractory prostate`, `androgen-independent prostate cancer`
- **Neuroendocrine Prostate Cancer**: `neuroendocrine prostate cancer`, `nepc`, `neuroendocrine differentiation prostate`, `small cell prostate`, `neuroendocrine carcinoma prostate`, `treatment-emergent neuroendocrine`
- **Neuroendocrine Tumors (Non-Prostate)**: `neuroendocrine tumor`, `net`, `neuroendocrine neoplasm`, `carcinoid tumor`, `pancreatic neuroendocrine`, `pnet`, `peptide receptor radionuclide`, `prrt`, `somatostatin receptor positive tumor`
- **Lung Cancer / High-Grade Neuroendocrine Lung**: `lung cancer`, `sclc`, `small cell lung cancer`, `high-grade neuroendocrine lung`, `dll3 lung`, `lung neuroendocrine carcinoma`, `pulmonary neuroendocrine`
- **Liver / Hepatocellular Cancer**: `liver cancer`, `hepatocellular carcinoma`, `hcc`, `hepatoma`, `primary liver cancer`, `alpha particle liver`, `radiopharmaceutical liver therapy`
- **Breast Cancer**: `breast cancer`, `breast carcinoma`, `her2-positive breast`, `triple negative breast`, `metastatic breast cancer`, `radioligand breast cancer`
- **Colorectal Cancer**: `colorectal cancer`, `colon cancer`, `rectal cancer`, `crc`, `colorectal carcinoma`, `radioligand colorectal`
- **Pancreatic Cancer**: `pancreatic cancer`, `pdac`, `pancreatic ductal adenocarcinoma`, `pancreatic carcinoma`, `radiopharmaceutical pancreatic`
- **Bone Metastases / Skeletal Involvement**: `bone metastases`, `skeletal metastases`, `osseous metastases`, `bone-targeted radionuclide`, `radium bone therapy`, `bone-seeking radiopharmaceutical`, `osteoblastic metastases`
- **Renal / Bladder / Urologic Cancers (Non-Prostate)**: `renal cell carcinoma`, `kidney cancer`, `bladder cancer`, `urothelial carcinoma`, `urologic cancer radioligand`, `renal cancer radionuclide`

The Cancer Type / Disease Context dimension has 52 of 115 projects unclassified, and among the 63 matched, hormone-sensitive prostate cancer is the most represented sub-type at 16 projects (13.9% of sample), while mCRPC - the disease context most associated with approved RLT agents - registers 0 projects in this sample (0.0%). Several off-prostate disease contexts appear (lung cancer at 4 projects, 3.5%; pancreatic cancer at 3 projects, 2.6%; bone metastases at 3 projects, 2.6%; neuroendocrine prostate cancer at 3 projects, 2.6%), reflecting interest in extending RLT platforms beyond primary prostate indications. The broader NIH count for mCRPC (65) stands out as the highest in this dimension and is substantially above the median for peer categories, which warrants attention but is addressed in the ranked opportunities section rather than as a dimension-level conclusion.

**Confidence: Medium** - Evidence: 63 of 115 projects matched; hormone-sensitive prostate cancer at 16 projects (13.9%), mCRPC at 0 projects (0.0%); 52 unclassified projects.

### Coverage by Translational / Development Dimension

*The stage of research or translational focus: from chemistry and radiochemistry through preclinical, clinical, dosimetry, safety, and personalization*

<!-- chart:white-space-dimension:4 -->

| Category | Projects | % of Sample | Funding | Broader NIH (radioligand therapy for prostate cancer) |
|----------|---------:|------------:|--------:|------------:|
| Chelator Chemistry & Radiochemistry Development | 4 | 3.5% | $1.7M | 2 |
| Ligand / Radiopharmaceutical Design & Synthesis | 33 | 28.7% | $32.8M | 3 |
| Preclinical In Vivo / Animal Model Studies | 21 | 18.3% | $15.0M | 6 |
| Dosimetry & Treatment Planning | 4 | 3.5% | $7.0M | 70 [†] |
| Toxicity, Safety & Off-Target Uptake Reduction | 3 | 2.6% | $2.8M | 18 |
| Biomarker-Guided Patient Selection & Personalization | 8 | 7.0% | $7.2M | 0 |
| Resistance Mechanisms & Tumor Microenvironment | 5 | 4.3% | $3.8M | 0 |
| Imaging / Diagnostic Companion Development (PET/SPECT) | 7 | 6.1% | $9.0M | 4 |
| Artificial Intelligence & Computational Methods for RLT | 1 | 0.9% | $1.1M | 0 |
| Clinical Trials & Clinical Outcome Evaluation | 7 | 6.1% | $3.8M | 0 |

> [†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

*Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 93 classified projects.*

*Keywords per category (what was counted):*

- **Chelator Chemistry & Radiochemistry Development**: `chelator`, `chelation chemistry`, `bifunctional chelator`, `dota`, `nota`, `macropa`, `chelator conjugate`, `radiolabeling chemistry`, `antibody chelator conjugate`, `novel chelator`, `macrocyclic chelator`
- **Ligand / Radiopharmaceutical Design & Synthesis**: `radiopharmaceutical design`, `ligand design`, `radioligand synthesis`, `radiolabeled compound`, `radiolabeled peptide`, `small molecule radioligand design`, `radiopharmaceutical development`, `psma ligand design`, `next-generation radiopharmaceutical`
- **Preclinical In Vivo / Animal Model Studies**: `preclinical`, `mouse model`, `xenograft`, `tumor-bearing mice`, `in vivo radioligand`, `animal model radionuclide`, `pdx model`, `syngeneic model`, `preclinical efficacy`, `preclinical toxicology`
- **Dosimetry & Treatment Planning**: `dosimetry`, `treatment planning`, `absorbed dose`, `dose calculation`, `psma rpt dosimetry`, `radiopharmaceutical dosimetry`, `personalized dosimetry`, `deep learning treatment planning`, `monte carlo dosimetry`, `internal dosimetry`
- **Toxicity, Safety & Off-Target Uptake Reduction**: `toxicity`, `off-target uptake`, `salivary gland uptake`, `kidney toxicity`, `bone marrow toxicity`, `adverse effect radionuclide`, `salivary gland dosimetry`, `organ toxicity radioligand`, `dose-limiting toxicity`, `safety evaluation radiopharmaceutical`
- **Biomarker-Guided Patient Selection & Personalization**: `biomarker-guided`, `patient selection biomarker`, `personalized radioligand`, `predictive biomarker rpt`, `companion biomarker`, `psma expression biomarker`, `molecular biomarker selection`, `theranostic biomarker`, `genomic biomarker radioligand`
- **Resistance Mechanisms & Tumor Microenvironment**: `resistance mechanism`, `radiopharmaceutical resistance`, `tumor microenvironment resistance`, `tme-mediated resistance`, `radioligand resistance`, `psma downregulation resistance`, `immune evasion radionuclide`, `tumor microenvironment radioligand`, `hypoxia radionuclide resistance`
- **Imaging / Diagnostic Companion Development (PET/SPECT)**: `pet imaging`, `spect imaging`, `gallium-68 psma`, `68ga-psma`, `diagnostic imaging radioligand`, `pet companion diagnostic`, `spect dosimetry imaging`, `theranostic imaging`, `nuclear imaging prostate`, `pet/ct radioligand`
- **Artificial Intelligence & Computational Methods for RLT**: `deep learning radioligand`, `machine learning dosimetry`, `ai treatment planning`, `deep learning psma`, `neural network radionuclide`, `computational radiopharmaceutical`, `image segmentation radionuclide`, `automated treatment planning rpt`
- **Clinical Trials & Clinical Outcome Evaluation**: `clinical trial radioligand`, `phase i radioligand`, `phase ii radiopharmaceutical`, `clinical outcome radionuclide`, `overall survival radioligand`, `psa response radioligand`, `clinical efficacy rpt`, `randomized trial radiopharmaceutical`, `vision trial`, `therap trial`

The Translational / Development Dimension has the highest match rate of all five dimensions at 93 of 115 projects, indicating that most projects in this sample can be assigned a translational stage or focus. Ligand/radiopharmaceutical design and synthesis is the most common category at 33 projects (28.7% of sample), followed by preclinical in vivo/animal model studies at 21 projects (18.3%) - each cited separately as rows are non-exclusive. Biomarker-guided patient selection and personalization (8 projects, 7.0%), resistance mechanisms and tumor microenvironment (5 projects, 4.3%), and artificial intelligence/computational methods (1 project, 0.9%) are each underrepresented relative to the upstream chemistry and preclinical clusters, suggesting the sample skews toward early-stage research rather than clinical translation, personalization, or computational optimization.

**Confidence: High** - Evidence: 93 of 115 projects matched; ligand design at 33 projects (28.7%), preclinical at 21 projects (18.3%); AI/computational methods at 1 project (0.9%).

### Coverage Gap Signals

*Candidate gaps ranked by **share-normalized** comparison: broader-NIH share of the scope universe divided by sample share. A category only ranks as a gap when its broader-share materially exceeds its sample-share (>=2x). Raw count ratios are misleading when the sample universe (115 projects) and scope universe (1,198 projects) differ in size, so the shares are computed against those denominators directly. Signals here are still **directional** - the sample uses semantic matching, broader-NIH uses title-only keyword matching, and vocabulary drift can shift shares in either direction.*

**1. Metastatic Castration-Resistant Prostate Cancer (mCRPC)** (Cancer Type / Disease Context)

- Analyzed sample: **0** projects (0.0% of 115 sample projects)
- Broader radioligand therapy for prostate cancer: **65** matching projects (5.4% of 1,198 scope universe)
- **Share ratio:** broader-share is nullx sample-share - this is what identifies the gap, not the raw count difference.
- **Small-sample caveat:** the ratio here rests on zero topic project. A single classification change to the topic sample could shift the signal substantially. Treat as directional only.

mCRPC is the disease stage for which RLT agents such as Lu-177 PSMA-617 have received regulatory approval, making its absence from this sample particularly striking - 0 of 115 projects (0.0% sample-share) versus 65 broader NIH matches, where the broader-share is substantially above what the sample-share of 0.0% would predict. This divergence suggests that mCRPC-specific work in this sample may be described through mechanism or agent language rather than explicit disease-stage labeling, or alternatively that NIH funding in this sample is concentrated upstream (design, preclinical, theranostics) while mCRPC clinical and translational work is pursued through other funding mechanisms or industry channels. For a researcher framing an R01 or U01, explicitly positioning a project within the mCRPC disease context - particularly around resistance, patient selection, or novel combinations - may differentiate a proposal from the predominantly upstream or disease-agnostic framing seen in this sample.

**Confidence: Medium** - Evidence: sample count = 0 of 115 (0.0% sample-share), broader NIH = 65; the zero sample count creates interpretive uncertainty about whether this reflects a labeling artifact or a funding gap.

### Strategic Implications

For a researcher writing an R01 or U01 in this space, the most quantitatively distinct positioning opportunity identified from the ranked white space analysis is an explicit focus on metastatic castration-resistant prostate cancer (mCRPC) as the primary disease context: this subtype accounts for 0 of 115 projects (0.0% sample-share) in the analyzed NIH funding sample, yet 65 broader NIH RePORTER matches indicate active federal engagement with the mCRPC space through adjacent or overlapping mechanisms. A proposal that anchors its specific aims in mCRPC - whether addressing acquired resistance to RLT, biomarker-guided patient selection for retreatment, or novel combination strategies in this disease state - would occupy a space largely absent from the current NIH RLT portfolio as captured here. Pairing mCRPC-specific disease framing with translational approaches that are also thin in the sample (such as computational dosimetry, AI-assisted treatment planning, or resistance mechanism characterization) could further sharpen differentiation in study section review. The medium confidence rating reflects uncertainty about whether the zero-project sample count for mCRPC is a labeling artifact or a substantive funding gap, which a targeted literature search or RePORTER query using abstract-level keywords could help resolve before proposal submission.

**Confidence: Medium** - Evidence: mCRPC at 0 of 115 sample projects (0.0% sample-share) vs. 65 broader NIH matches; single ranked opportunity limits the breadth of strategic inference.



---

## Research Positioning

### Competitive Positioning

Among the funded projects, three distinct positioning clusters are visible: (1) PSMA-targeted radioligand therapy optimization - including dosimetry personalization (5R01CA289631-02), PSMA expression modulation (5R01CA235741-06), and salivary gland toxicity mitigation (R01CA262675, 1R41CA285188-01A1) - representing the most densely occupied space with multiple concurrent approaches at several organizations; (2) combination strategies pairing radiopharmaceutical therapy with immunotherapy, vaccination, or external beam radiation (P01CA250972, 5R01CA240779-06, ZIABC011895), which span at least 8 projects and represent an active but still mechanistically heterogeneous area; and (3) alternative target development beyond PSMA, including CD46 (R01CA279203), DLL3 (R01CA286918), androgen receptor radiopharmaceuticals (K99CA312787), and kallikrein-2 (R01CA308884), where project counts per target remain low and preclinical validation is ongoing.

**Confidence: High** - Evidence: 30+ projects across the full project list address PSMA-centric approaches; at least 8 projects explicitly frame combination therapy; alternative-target projects number approximately 6-8 distinct targets with 1-2 projects each.

A new entrant seeking differentiation faces the most competition in PSMA dosimetry and PSMA ligand chemistry, while alternative tumor antigens with theranostic potential and resistance mechanism characterization remain comparatively sparse within the sample.

### Multi-Method Concentration Patterns

In this sample, the largest single-institution project cluster comprises 11 projects at University of California, San Francisco spanning PSMA expression biology (5R01CA235741-06), CD46 radioimmunotherapy (R01CA279203), dosimetry biomarkers (R01CA240582), metabolic MRI monitoring (5R01CA256740-05), combination immunotherapy infrastructure (P50CA275741), kallikrein-2 theranostics (R01CA308884), hyperpolarized C-13 MRI (5R01CA238379-05), TGFb theranostics (5R01CA297601-02), membrane-binding probe activation (5R01CA279328-03), PARP inhibitor imaging (5R01CA266013 equivalent), and a training award (K99CA304511) - covering therapeutic, diagnostic, basic research, and infrastructure categories across a single node.

**Confidence: High** - Evidence: $12.5M, 11 projects confirmed in the funding-by-org table, categories confirmed across the full project list.

Sloan-Kettering (10 projects, $8.1M) shows a distinct concentration in theranostic isotope chemistry (R35CA232130 on Pb-203/212), DLL3 biology (R01CA286918), PSMA radiosensitization (5R03CA286680-02), AR radiopharmaceuticals (K99CA312787), toxicity mitigation (R01CA262675), and clinical biomarker qualification (5R01CA240759-06), spanning basic research through clinical translation stages within a single institution.

**Confidence: High** - Evidence: 10 projects confirmed, $8.1M.

University of Wisconsin-Madison holds 8 projects concentrated at the intersection of radionuclide therapy and immunomodulation - including the P01CA250972 program project on vaccine-TRT combinations, a training award (F31CA305954), infrastructure projects (5P50CA275595-09, 5P50CA269011-03), CAR-T radionuclide combinations (5K08CA285941-02), and isotope chemistry tools (R01EB032349) - representing a methodologically coherent cluster around immune-radiation synergy.

**Confidence: High** - Evidence: 8 projects, $4.6M confirmed.

### Methodological Trends

Alpha-particle emitter development represents the most consistently growing methodological theme within the analyzed sample, appearing across at least 10 projects spanning multiple isotopes (Ac-225, Pb-212, Ra-223, At-211) and multiple tumor types - including dedicated chelator chemistry programs (R01EB039679, R56EB029259, R01EB032349), preclinical alpha-PRRT work (5R01CA243014-06), Ra-223 combination optimization (R01CA240711), and PSMA-targeted alpha therapy toxicity work (R01CA262675) - suggesting a field-wide push to move beyond Lu-177 beta emitters toward higher-LET options.

**Confidence: High** - Evidence: 10+ projects across the full project list explicitly name alpha emitters or Pb-203/212/Ac-225/Ra-223 as the primary modality, spanning at least 6 distinct institutions.

Dosimetry personalization and AI-assisted treatment planning are emerging as a distinct methodological layer within the sample, with at least 3 projects (5R01CA289631-02 at Michigan, 5R01CA296305-02 at Yale, 5R01CA240706-05 at Michigan) framing fixed-activity dosing as a core limitation and proposing absorbed-dose prediction or deep learning replanning as the intervention - though three projects across two institutions is a moderate signal, not a dominant one.

**Confidence: Medium** - Evidence: 3 projects, ~$2.0M combined, two institutions.

The combination of radiopharmaceutical therapy with immune modulation - through checkpoint inhibitors, tumor-specific vaccines, CAR-T cells, or antibody-drug conjugates - appears across at least 8 funded projects (P01CA250972, ZIABC011895, R01CA269221-03, 5R01CA287491-02, K99CA304511, F31CA305954, 3P01CA250972-05S1, R01CA315741), marking a transition in the sample from single-modality radiopharmaceutical development toward mechanistically rationale-driven combinations; the mechanistic diversity across these projects (different immune targets, timing strategies, and tumor contexts) suggests this area has not yet converged on a dominant combination paradigm.

**Confidence: High** - Evidence: 8+ projects confirmed across the full project list, spanning training awards through P01 program projects, multiple institutions.



---

## NIH Funding Landscape

Among the examined projects, our analysis reveals a dominant focus on PSMA-targeted radioligand therapy (RLT) for metastatic castration-resistant prostate cancer, with Precise-tier projects concentrated on three interlocking challenges: modulating PSMA expression to improve target engagement (e.g., the MELT program at UCSF), personalizing dosimetry through AI-driven treatment planning and absorbed-dose prediction (Yale, University of Michigan), and overcoming resistance by combining RLT with immunotherapy or vaccination (University of Wisconsin-Madison, UCLA). The sample totals approximately $105.9M across 115 projects, with FY2024 at $40.9M and FY2025 at $51.2M - though two data points do not establish a trend - and FY2026 YTD at $13.8M reflecting only partial-year reporting. A secondary priority visible in the sample is expanding the radionuclide toolkit: multiple projects pursue alpha-emitting isotopes (Ra-223, Pb-212, At-211) and novel chelator chemistry to improve therapeutic index and enable matched theranostic imaging pairs. UCSF ($12.5M), the NCI Division of Basic Sciences ($12.4M), and Johns Hopkins ($9.0M) are the top-funded organizations in the sample, suggesting that both intramural NCI programs and a handful of high-volume academic centers are anchoring the majority of examined investment.

### Funding Summary

*Funding figures sum award amounts across all budget periods for each project. Each fiscal year reflects actual spend in that year, not the most recent budget period only. Totals only include projects that meet the topic-relevance threshold - umbrella support grants (e.g., P30 cancer centers) that host a relevant trial but cover many unrelated programs are intentionally excluded so the headline number stays topically attributable.*

| Metric | Value |
|--------|-------|
| Total Committed Funding | $105.9M |
| Active Projects | 115 |
| Funding Organizations | 52 |
| Principal Investigators | 125 |

### Funding by Year

<!-- chart:funding-by-year -->

| Year | Projects | Funding |
|------|----------|--------|
| FY2026 (YTD) | 27 | $13.8M |
| FY2025 | 78 | $51.2M |
| FY2024 | 77 | $40.9M |

*The Projects column counts each project in every year it received funding, so per-year counts sum to more than the 115-project sample total. Funding amounts are actual per-year spend from NIH RePORTER budget-period rows.*

*Through September 2026; FY2026 ends Sep 30, 2026. The YTD figure should not be compared directly to fully-reported prior years.*

### Top Funding Categories

<!-- chart:categories -->

| Category | Projects | Funding |
|----------|----------|--------|
| Therapeutics | 81 | $77.2M |
| Basic Research | 9 | $11.9M |
| Biotools | 8 | $8.7M |
| Diagnostics | 6 | $4.3M |
| Infrastructure | 5 | $2.6M |
| Training | 5 | $807K |
| Medical Device | 1 | $405K |



---

## Key Research Projects

### Top Projects by Relevance

*Projects are ranked by semantic similarity to the topic - the most topic-relevant funded work first, not the largest awards. Funding is shown on each card as scale context (sum of award totals across all budget periods for each project). Latest activity is the most recent fiscal year the project received an award. Category is auto-assigned by AI classification and may occasionally misassign monitoring-oriented diagnostic projects as therapeutics - the abstract is the ground truth for what the project actually does.*

#### 1. PSMA ligand radiosensitizers to improve the therapeutic index of external beam radiotherapy for prostate cancer
- **PI:** HIGGINSON, DANIEL, Sloan-Kettering Inst Can Research
- **Funding:** $176K (latest activity FY2025)
- **Category:** Therapeutics

**Insight:** Adjacent to radioligand therapy for prostate cancer via shared PSMA targeting and prostate cancer disease area; not a radioligand therapy for prostate cancer project itself. This project develops PSMA-targeted radiosensitizer drugs designed to enhance external beam radiotherapy rather than deliver systemic radionuclide doses, focusing on tumor-selective sensitization to spare adjacent normal tissues such as bowel.

> Radiation therapy is commonly used to cure prostate cancers, including cancers confined to the prostate gland itself as well as prostate cancer that has spread to surrounding lymph nodes or other tissues. However, many patients are not cured of prostate cancer after radiotherapy due to restrictions ...

[View Project ->](https://www.granted.bio/project/11057708)

#### 2. Improving PSMA-based radioligand therapy via combination radioligand therapy
- **PI:** LIN, FRANK  (contact), Division of Basic Sciences - Nci
- **Funding:** $321K (latest activity FY2025)
- **Category:** Therapeutics

**Insight:** This project directly addresses improving PSMA-based radioligand therapy through combination radioligand therapy approaches, positioning it within the active NIH push to move beyond single-agent 177Lu-PSMA regimens. No abstract is available, limiting specific methodological assessment, but the title and funding category confirm a therapeutics orientation aligned with the combination therapy axis identified across multiple funded projects.

[View Project ->](https://www.granted.bio/project/11414272)

#### 3. MELT: Modulation of PSMA Expression for Lutetium Therapy
- **PI:** HOPE, THOMAS A., University of California, San Francisco
- **Funding:** $1.1M (latest activity FY2025)
- **Category:** Therapeutics

**Insight:** This project tackles a mechanistic question central to PSMA radioligand therapy outcomes: whether tumor response is governed by intrinsic radiosensitivity or by the magnitude of absorbed radiation dose, and how PSMA expression levels are regulated in that context. By pursuing co-administered therapies to upregulate PSMA expression or potentiate radiosensitivity, the work addresses a documented clinical problem - heterogeneous and loss-of-target resistance - without an approved solution, placing it in a translational gap within the current 177Lu-PSMA-617 commercial experience.

> In this proposal, we will study a radioligand therapy (RLT) that targets the prostate specific membrane antigen (PSMA), a molecule that is expressed on the majority of prostate cancer cells. PSMA RLT relies on two basic premises: targeting the radiation to PSMA and the radiosensitivity of the tissue...

[View Project ->](https://www.granted.bio/project/11128647)

#### 4. Targeting tumor microenvironment-mediated radiopharmaceutical therapy resistance in prostate cancer
- **PI:** ABT, EVAN ROBERT, University of California Los Angeles
- **Funding:** $405K (latest activity FY2025)
- **Category:** Medical Device

**Insight:** This project explicitly targets immuno-metabolic resistance mechanisms that drive relapse after radiopharmaceutical therapy for metastatic castration-resistant prostate cancer, combining expertise in immune signaling and RPT at UCLA. It is one of at least two RPT-resistance projects in the analyzed sample with complementary preclinical tools not yet integrated across sites, and its focus on tumor microenvironment immune pathways directly addresses why durable responses remain rare despite FDA-approved agents.

> FDA approval of radiopharmaceutical therapy (RPT) for the treatment of metastatic castration-resistant prostate cancer in 2022 represented a paradigm shift in the management of this incurable malignancy. However, resistance and relapse occur uniformly. This proposal outlines a new collaboration betw...

[View Project ->](https://www.granted.bio/project/11211799)

#### 5. Enhancing radioligand therapy for prostate cancer with biomarker and dosimetry guided personalization
- **PI:** DEWARAJA, YUNI K, University of Michigan at Ann Arbor
- **Funding:** $644K (latest activity FY2025)
- **Category:** Therapeutics

**Insight:** This project directly develops personalized dosimetry-guided radioligand therapy for prostate cancer, proposing absorbed dose predictions as a replacement for the fixed-activity dosing used in current clinical practice including 177Lu-PSMA-617 treatment. The biomarker-plus-dosimetry pairing is methodologically specific: it aims to predict which patients will achieve durable responses before or during treatment, a capability absent from any approved dosing protocol and relevant to the SPECT-based dosimetry development thread running across multiple funded projects in this portfolio.

> The proposed research is relevant to public health because it focuses on developing an alternative strategy for radiopharmaceutical therapy that enables optimized, personalized dosing based on absorbed dose predictions. Such an approach is expected to result in durable responses in cancer patients t...

[View Project ->](https://www.granted.bio/project/11193875)

#### 6. Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation
- **PI:** MCNEEL, DOUGLAS G. (contact), University of Wisconsin-Madison
- **Funding:** $2.4M (latest activity FY2024)
- **Category:** Therapeutics

**Insight:** This project tests low-dose targeted radionuclide therapy combined with anti-tumor vaccination in prostate cancer, a disease classified as immunologically cold, with the explicit goal of expanding antigen-specific CD8+ T-cell infiltration. It is one of at least five combination immunotherapy projects in the analyzed sample and is embedded within a larger multi-project program at University of Wisconsin-Madison, giving it access to shared preclinical infrastructure; the low-dose TRT framing is a deliberate mechanistic choice, using radiation to prime immunity rather than ablate tumor bulk, which distinguishes it from standard therapeutic dosing studies.

> PROJECT 4 We have recently identified that targeted radionuclide therapy (TRT) at doses lower than those that cause direct anti-tumor effects and in combination with anti-tumor vaccination can elicit greater anti-tumor effects than either treatment alone. Given that both of these approaches are in c...

[View Project ->](https://www.granted.bio/project/10873219)

#### 7. Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
- **PI:** MENDA, YUSUF, University of Iowa
- **Funding:** $167K (latest activity FY2024)
- **Category:** Therapeutics

**Insight:** Adjacent to radioligand therapy for prostate cancer via shared theranostic methodology (Pb-203/212 pairing) and alpha-emitter peptide receptor radionuclide therapy development; not a radioligand therapy for prostate cancer project itself. The primary disease target here is neuroendocrine tumors using DOTATATE-based PRRT, and while the Pb-203/Pb-212 theranostic pairing and image-guided personalized dosimetry methods are directly transferable to prostate cancer alpha-emitter programs noted in the executive summary, the project does not address prostate cancer.

> Peptide receptor radionuclide therapy (PRRT) with [177Lu]DOTATATE improves quality of life and survival in patients with advanced neuroendocrine tumors; however objective tumor regression is infrequent and complete responses are exceedingly rare. On the other hand, exciting-emerging evidence suggest...

[View Project ->](https://www.granted.bio/project/10850995)

#### 8. Systematic Testing of a TGFβ Targeted Theranostic in Preclinical Cancer
- **PI:** BARCELLOS-HOFF, MARY HELEN, University of California, San Francisco
- **Funding:** $1.3M (latest activity FY2026)
- **Category:** Therapeutics

**Insight:** Adjacent to radioligand therapy for prostate cancer via shared radiopharmaceutical therapy methodology and explicit mention of prostate cancer as one of three cancers where RPT benefit is established; not a radioligand therapy for prostate cancer project itself. This project tests a TGFβ-targeted theranostic across multiple cancer models as a tumor-agnostic radiopharmaceutical, with efficacy correlated against microenvironment and immune mechanisms of radiation sensitivity - a methodology that treats prostate cancer as a reference point rather than the primary indication.

> The clear benefit of RPT in thyroid, prostate and neuroendocrine cancers might be expanded across cancers by using a tumor agnostic radiopharmaceutical. The goal of this proposal is to test a theranostic targeted to dysregulated TGFβ activity in multiple cancer models, and to correlate overall tumor...

[View Project ->](https://www.granted.bio/project/11248374)

#### 9. Deep Learning-Based Treatment Planning for PSMA RPT
- **PI:** EL FAKHRI, GEORGES, Yale University
- **Funding:** $1.1M (latest activity FY2026)
- **Category:** Therapeutics

**Insight:** This project develops deep learning models to predict tumor and healthy tissue dosimetry for 177Lu-PSMA radiotherapy of metastatic castration-resistant prostate cancer, with the explicit aim of enabling personalized dose prescription and dynamic replanning. Alongside the University of Michigan dosimetry project (11193875), it represents a paired effort within the analyzed sample to replace fixed-activity treatment with AI-assisted absorbed dose prediction - a convergence of computational and imaging methods targeting the same gap in current clinical practice.

> The goals of this project are to develop AI-assisted predictive models of dosimetry in 177Lu-PSMA radiotherapy of metastatic castration resistant prostate cancers. We aim to develop deep learning-based models to predict tumor and healthy tissue dosimetry, with the goal of creating a tool that may be...

[View Project ->](https://www.granted.bio/project/11252311)

#### 10. Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate
- **PI:** BODEI, LISA  (contact), Sloan-Kettering Inst Can Research
- **Funding:** $1.4M (latest activity FY2025)
- **Category:** Basic Research

**Insight:** Adjacent to radioligand therapy for prostate cancer via shared theranostic antibody methodology and explicit inclusion of neuroendocrine prostate cancer as a target indication; not a radioligand therapy for prostate cancer project itself. The DLL3-targeting radiolabeled antibody SC16.56 is being evaluated in both small cell lung cancer and neuroendocrine prostate cancer, and the theranostic design - PET imaging paired with therapeutic radiolabeling - mirrors the PSMA-targeted theranostic paradigm, but the driving antigen and primary disease contexts differ from the PSMA-based prostate cancer radioligand therapy projects that dominate this portfolio.

> An antigen known as DLL3 is expressed on the cell surface of two rapidly lethal types of cancer (small cell lung cancer and neuroendocrine prostate cancer) and can be targeted with a radiolabeled antibody that delivers radiation to the site of disease. This antibody, SC16.56, can be used for both di...

[View Project ->](https://www.granted.bio/project/11129769)



---

## Market Context

### Market Overview

*Market context below is synthesized from current web search results. See sources at the end of this section. NIH funding patterns are integrated to bridge public research and commercial activity.*

Radioligand therapy (RLT) for prostate cancer has become one of the most commercially dynamic segments in oncology, anchored by the PSMA-targeted beta-emitter lutetium-177 vipivotide tetraxetan (Pluvicto, Novartis). Originally approved by the FDA in 2022 for post-taxane metastatic castration-resistant prostate cancer (mCRPC) based on the Phase III VISION trial, Pluvicto has since accumulated two additional U.S. approvals: a March 2025 label expansion for taxane-naive mCRPC patients previously treated with an ARPI (based on Phase III PSMAfore, which showed a 59% reduction in risk of radiographic progression or death versus ARPI switch), and an August 2026 approval for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC) based on Phase III PSMAddition (33% risk reduction in progression or death per the updated HR 0.67 analysis when added to ARPI plus ADT, with an immature and not-yet-significant OS trend, HR 0.80, CI 0.63-1.01). Pluvicto has also received NMPA approval in China and public funding in several Canadian provinces. Web-sourced estimates put prostate cancer at approximately 58% of the overall RLT market by indication in 2025, with PSMA-targeted agents holding roughly 61% market share by receptor target; these are third-party market figures rather than sample-derived counts.

The market's expansion is being driven by three concurrent forces: widening approved indications for Pluvicto (which Novartis projects at up to $5 billion in peak sales), an accelerating next-generation pipeline targeting both beta- and alpha-emitting isotopes, and a manufacturing scale-up to address earlier supply constraints. Novartis now has five manufacturing sites operational or under construction in the U.S. A competitive wave of late-stage assets is advancing - including Eli Lilly's PNT2002 (Lu-177, PSMA-targeted, Phase III), AstraZeneca/Fusion Pharmaceuticals' FPI-2265 (Ac-225, PSMA-targeted, Phase II), Curium Pharma's 177Lu-PSMA-I&T (Phase III ECLIPSE), Clarity Pharmaceuticals' 67Cu-SAR-bisPSMA, and ARTBIO's AB001 (Pb-212 alpha emitter, Phase I) - while Novartis itself is investigating its own Ac-225-PSMA-617 in late-stage development. Bayer's Xofigo (radium-223), the first FDA-approved alpha-emitting radiopharmaceutical for prostate cancer with bone metastases, remains an approved option though its addressable population is narrower.

The RLT market broadly faces real operational challenges that remain unresolved: isotope supply chain complexity (radioisotopes decay rapidly and require specialized short-window delivery logistics), nuclear medicine infrastructure gaps outside major academic centers, and a reimbursement environment that is still evolving for newer indications. Alpha-emitter programs - including actinium-225 and lead-212 platforms - are generating significant pipeline interest but remain pre-approval in prostate cancer. The theranostic model (PSMA PET imaging to confirm target expression before therapy) is both a strength (patient selection) and a practical bottleneck (requires qualified imaging infrastructure). Within the analyzed sample, reimbursement and access data for real-world populations outside academic settings are thinly represented relative to the volume of trial-level evidence now available.

**Market Sizing:** $2.98 billion in 2025, projected to $15.85 billion by 2035 at an 18.2% CAGR (SNS Insider, September 2026). Note: this covers the broader global radioligand therapy market across all indications; prostate cancer accounted for approximately 58% of indication share in 2025. Firm estimates across research houses range from $2.65 billion to $3.32 billion for 2025, reflecting differing scope and methodology.

### Key Players

*These players are identified from market reports and trade press, and may differ from the NIH-funded organizations analyzed elsewhere in this report.*

- Novartis (Pluvicto / 177Lu-PSMA-617; 225Ac-PSMA-617 pipeline; Mariana Oncology acquisition)
- Eli Lilly (PNT2002 / PNT2003 via Point Biopharma acquisition; Aktis Oncology deal; Radionetics alliance)
- AstraZeneca (FPI-2265 / Fusion Pharmaceuticals acquisition)
- Bristol Myers Squibb / RayzeBio (RYZ101 Ac-225; RYZ801; OncoACP3 via Philochem deal)
- Bayer (Xofigo / radium-223, alpha-emitter TAT programs)
- Curium Pharma (177Lu-PSMA-I&T, ECLIPSE Phase III)
- Telix Pharmaceuticals (TLX591-Tx therapeutic; Illuccix/Gozellix PSMA diagnostics)
- Lantheus Holdings (radiopharmaceutical diagnostics and therapy pipeline)
- ITM Isotope Technologies Munich (177Lu-edotreotide / ITM-11)
- Clarity Pharmaceuticals (67Cu-SAR-bisPSMA)
- ARTBIO (AB001, Pb-212 alpha RLT, Phase I mCRPC)
- Convergent Therapeutics (Ac-225 radioantibody, Phase II PSMA mCRPC)
- Perspective Therapeutics
- Sanofi
- Ariceum Therapeutics

### Recent Developments

- 2023-10: Eli Lilly acquired Point Biopharma for $1.4 billion, gaining PSMA-targeted PNT2002 (Lu-177, Phase III in mCRPC) and a manufacturing base in Indianapolis.
- 2023-12: Bristol Myers Squibb acquired RayzeBio for $4.1 billion, gaining an actinium-225 alpha-emitter platform including RYZ101 and prostate-cancer-targeted pipeline assets.
- 2024-03: AstraZeneca acquired Fusion Pharmaceuticals for approximately $2.4 billion (about $2 billion upfront), gaining FPI-2265 (Ac-225, PSMA-targeted) in Phase II for mCRPC and other radioconjugate programs.
- 2024-05: Novartis acquired Mariana Oncology for up to approximately $1.75 billion ($1 billion upfront plus milestones), adding preclinical RLT assets to reinforce its pipeline lead.
- 2024-Q3: Eli Lilly struck a deal with Aktis Oncology worth up to $1.1 billion and established a separate alliance with Radionetics Oncology, further expanding its radiopharmaceutical portfolio.
- 2025-03: FDA expanded Pluvicto label to cover taxane-naive PSMA-positive mCRPC patients previously treated with an ARPI, based on Phase III PSMAfore data (59% reduction in radiographic progression or death vs. ARPI switch), approximately tripling the eligible patient population.
- 2025-03: Curium Pharma completed the acquisition of Eczacibasi-Monrol's nuclear business, significantly expanding its Lu-177 manufacturing capacity.
- 2025-06: BMS/RayzeBio signed a deal with Swiss biotech Philochem, paying $350 million upfront for OncoACP3, a Phase I ACP3-targeted radiopharmaceutical for prostate cancer diagnostics and therapy.
- 2025-07: BMS/RayzeBio inaugurated a $160 million radiopharmaceutical manufacturing plant in Indianapolis.
- 2025-11: Pluvicto received NMPA approval in China, becoming the first PSMA radioligand therapy approved in that market.
- 2025-11: ITM Isotope Technologies announced FDA acceptance of its NDA filing review for 177Lu-edotreotide (ITM-11) for neuroendocrine tumors.
- 2026-01: ARTBIO began dosing patients in the ARTISAN Phase I trial of AB001, a Pb-212 alpha radioligand therapy for mCRPC, including patients with and without prior Lu-177 PSMA therapy exposure.
- 2026-01: Telix Pharmaceuticals announced FY2025 revenues of approximately $804 million, driven largely by the U.S. launch of Gozellix (PSMA PET diagnostic), supporting the theranostic infrastructure underpinning RLT.
- 2026-01: Zonsen PepLib Biotech announced a global licensing agreement with Novartis for an undisclosed peptide-based RLT candidate.
- 2026-05: PSMAddition Phase III data presented at ASCO 2026, showing Pluvicto plus standard of care reduced progression or death risk by 33% (updated analysis HR 0.67) in mHSPC, with a positive but immature OS trend (HR 0.80; CI 0.63-1.01).
- 2026-07: Eli Lilly advanced 177Lu-PNT2002 into a pivotal Phase III trial for biochemically recurrent prostate cancer, broadening its PSMA RLT development beyond mCRPC.
- 2026-08: FDA approved Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC) in combination with an ARPI, based on PSMAddition Phase III data, making Pluvicto the only PSMA-targeted agent approved across the full metastatic prostate cancer spectrum and nearly doubling the eligible patient population.

### Competitive Landscape

The radioligand therapy prostate cancer space is dominated commercially by Novartis, whose Pluvicto now spans three approved settings (post-taxane mCRPC, taxane-naive mCRPC, and mHSPC) and generated approximately $2.0 billion in full-year 2025 sales. The 2023-2024 M&A wave - BMS/RayzeBio ($4.1B), AstraZeneca/Fusion ($2.4B), Eli Lilly/Point Biopharma ($1.4B), and Novartis/Mariana (~$1.75B) - has consolidated most of the leading late-stage assets within large pharma, shifting competition from biotech-versus-biotech to a multi-front contest among well-capitalized incumbents. The next wave of differentiation centers on isotope choice: lutetium-177 beta-emitters (Pluvicto, PNT2002, Curium's 177Lu-PSMA-I&T) face potential competition from actinium-225 and lead-212 alpha-emitters (FPI-2265, RYZ101, AB001), which are hypothesized to carry higher cytotoxicity and shorter particle range, though none has yet cleared Phase III in prostate cancer. Manufacturing capacity and isotope supply chain reliability are competitive risks that could reshape the field as indications expand and patient volumes grow. Telix and Lantheus are building competitive moats on the diagnostic side, where PSMA PET imaging is a prerequisite for patient selection under the theranostic model. Smaller biotechs - Convergent Therapeutics, Perspective Therapeutics, Clarity Pharmaceuticals, Ariceum, and ARTBIO - are advancing differentiated targeting approaches (radioantibodies, copper-64/67, alternative tumor antigens) that may carve out niches if alpha-emitter or alternative-isotope data mature. Reimbursement access, nuclear medicine center capacity outside major academic hubs, and isotope logistics remain practical adoption barriers that all players must navigate, and real-world utilization data continue to lag the volume of regulatory and clinical trial evidence.

### Sources

*Live web sources retrieved during report generation. Click to verify.*

- [www.datamintelligence.com/research-report/radioligand-therapy-market](https://www.datamintelligence.com/research-report/radioligand-therapy-market)
- [www.fortunebusinessinsights.com/prostate-cancer-radiation-therapeutics-market-112713](https://www.fortunebusinessinsights.com/prostate-cancer-radiation-therapeutics-market-112713)
- [straitsresearch.com/press-release/global-radioligand-therapy-market-size](https://straitsresearch.com/press-release/global-radioligand-therapy-market-size)
- [www.snsinsider.com/reports/radioligand-therapy-market-10781](https://www.snsinsider.com/reports/radioligand-therapy-market-10781)
- [www.polarismarketresearch.com/industry-analysis/radiotheranostics-market](https://www.polarismarketresearch.com/industry-analysis/radiotheranostics-market)
- [www.globenewswire.com/news-release/2026/09/08/3357280/0/en/radioligand-therapy-market-to-grow-from-usd-2-98-billion-in-2025-to-usd-15-85-billion-by-2035-at-a-cagr-of-18-2-sns-insider.html](https://www.globenewswire.com/news-release/2026/09/08/3357280/0/en/radioligand-therapy-market-to-grow-from-usd-2-98-billion-in-2025-to-usd-15-85-billion-by-2035-at-a-cagr-of-18-2-sns-insider.html)
- [www.insightaceanalytic.com/report/global-radioligand-therapy-market/1281](https://www.insightaceanalytic.com/report/global-radioligand-therapy-market/1281)
- [www.precedenceresearch.com/radioligand-therapy-market](https://www.precedenceresearch.com/radioligand-therapy-market)
- [www.grandresearchstore.com/life-sciences/global-radiolig-therapy-drugs-for-cancer-market/amp](https://www.grandresearchstore.com/life-sciences/global-radiolig-therapy-drugs-for-cancer-market/amp)
- [www.marketsandmarkets.com/ResearchInsight/radioligand-therapy-rlt-companies.asp](https://www.marketsandmarkets.com/ResearchInsight/radioligand-therapy-rlt-companies.asp)



---

## Clinical Development Pipeline

*Note: This analysis includes only clinical trials linked to NIH-funded projects. Industry-sponsored and international trials may exist outside this sample.*

The trial distribution linked to this sample spans a broad range of statuses: the majority are in progress, planned, or completed, while a meaningful subset - including at least 52 terminated and 7 suspended trials across the broader linked pool - indicates that the field has encountered real execution and efficacy setbacks, and the pipeline should not be read as uniformly advancing. Within the prostate cancer-specific trials, metastatic castration-resistant prostate cancer (mCRPC) is the predominant condition targeted, with interventions including dose-escalation strategies for 177Lu-PSMA-617, SPECT/CT dosimetry studies during Pluvicto therapy, and a trial investigating vorinostat to upregulate PSMA expression in PSMA-low disease - directly reflecting the MELT scientific theme in the funded research. Earlier-phase trials (Phase 1 and Early Phase 1) explore alpha-emitting agents such as 212Pb-Pentixather for neuroendocrine tumors, and a first-in-human alpha-radiation imaging agent study, suggesting translational momentum from preclinical alpha-particle work into initial human safety evaluation. Combination approaches are also visible in the linked pipeline, including concurrent metastasis-directed external beam radiotherapy with Lu-PSMA and radiopharmaceutical-plus-immunotherapy regimens, consistent with the combination-therapy emphasis seen across the funded project sample.

### Trial Summary

<!-- chart:trials-by-phase -->

**By Phase**

| Phase | Count |
|-------|-------|
| Phase 1 | 148 |
| Phase 2 | 187 |
| Phase 3 | 43 |
| N/A | 122 |

**By Status**

| Status | Count |
|--------|-------|
| Recruiting | 88 |
| Enrolling By Invitation | 2 |
| Not Yet Recruiting | 13 |
| Completed | 244 |
| Terminated | 52 |
| Suspended | 7 |
| Withdrawn | 15 |
| Unknown Status | 9 |
| Active, Not Recruiting | 70 |

### Active Trials

#### 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
- **NCT ID:** [NCT07608627](https://www.granted.bio/trial/NCT07608627)
- **Phase:** PHASE1
- **Status:** NOT YET RECRUITING
- **Sponsor:** City of Hope Medical Center
- **Conditions:** Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- **Enrollment:** 15 participants

#### CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma
- **NCT ID:** [NCT07659678](https://www.granted.bio/trial/NCT07659678)
- **Phase:** PHASE2
- **Status:** NOT YET RECRUITING
- **Sponsor:** Washington University School of Medicine
- **Conditions:** Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck Squamous Cell Carcinoma HNSCC
- **Enrollment:** 90 participants

#### Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer
- **NCT ID:** [NCT07682649](https://www.granted.bio/trial/NCT07682649)
- **Phase:** PHASE1
- **Status:** NOT YET RECRUITING
- **Sponsor:** University of Michigan Rogel Cancer Center
- **Conditions:** Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- **Enrollment:** 20 participants

#### A Safety Study of 212Pb-Pentixather Radioligand Therapy
- **NCT ID:** [NCT05557708](https://www.granted.bio/trial/NCT05557708)
- **Phase:** EARLY_PHASE1
- **Status:** NOT YET RECRUITING
- **Sponsor:** Yusuf Menda
- **Conditions:** Carcinoid Tumor Lung, Neuroendocrine Tumor of the Lung, Carcinoma, Small-Cell Lung
- **Enrollment:** 20 participants

#### Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
- **NCT ID:** [NCT07197671](https://www.granted.bio/trial/NCT07197671)
- **Phase:** PHASE1
- **Status:** RECRUITING
- **Sponsor:** University of Wisconsin, Madison
- **Conditions:** Metastatic Cancer
- **Enrollment:** 60 participants

#### Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial
- **NCT ID:** [NCT07276438](https://www.granted.bio/trial/NCT07276438)
- **Phase:** Not specified
- **Status:** RECRUITING
- **Sponsor:** Jonsson Comprehensive Cancer Center
- **Conditions:** Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- **Enrollment:** 186 participants

#### Mental Health App for Cancer Survivors Study
- **NCT ID:** [NCT06472726](https://www.granted.bio/trial/NCT06472726)
- **Phase:** Not specified
- **Status:** TERMINATED
- **Sponsor:** University of Wisconsin, Madison
- **Conditions:** Head and Neck Cancer, Head and Neck Cancers, Depression
- **Enrollment:** 1 participants

#### PET [89Zr]DFO-starPEG in Solid Tumors
- **NCT ID:** [NCT06894745](https://www.granted.bio/trial/NCT06894745)
- **Phase:** PHASE1
- **Status:** RECRUITING
- **Sponsor:** Robert Flavell, MD, PhD
- **Conditions:** Solid Tumor, Solid Carcinoma, Soft Tissue Lesion
- **Enrollment:** 13 participants

#### SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
- **NCT ID:** [NCT06389097](https://www.granted.bio/trial/NCT06389097)
- **Phase:** Not specified
- **Status:** RECRUITING
- **Sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Conditions:** Prostate Cancer, Advanced Cancer
- **Enrollment:** 80 participants

#### SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
- **NCT ID:** [NCT07096999](https://www.granted.bio/trial/NCT07096999)
- **Phase:** Not specified
- **Status:** RECRUITING
- **Sponsor:** University of Michigan Rogel Cancer Center
- **Conditions:** Metastatic Castration-Resistant Prostate Carcinoma
- **Enrollment:** 60 participants

#### Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
- **NCT ID:** [NCT06236139](https://www.granted.bio/trial/NCT06236139)
- **Phase:** PHASE1
- **Status:** RECRUITING
- **Sponsor:** Fred Hutchinson Cancer Center
- **Conditions:** Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- **Enrollment:** 48 participants

#### Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- **NCT ID:** [NCT06391034](https://www.granted.bio/trial/NCT06391034)
- **Phase:** PHASE2
- **Status:** RECRUITING
- **Sponsor:** Robert Bok, MD, PhD
- **Conditions:** Prostate Cancer
- **Enrollment:** 161 participants

#### Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
- **NCT ID:** [NCT06308913](https://www.granted.bio/trial/NCT06308913)
- **Phase:** EARLY_PHASE1
- **Status:** ACTIVE, NOT RECRUITING
- **Sponsor:** University of Wisconsin, Madison
- **Conditions:** Head and Neck Squamous Cell Carcinoma
- **Enrollment:** 12 participants

#### Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
- **NCT ID:** [NCT06145633](https://www.granted.bio/trial/NCT06145633)
- **Phase:** PHASE2
- **Status:** RECRUITING
- **Sponsor:** Fred Hutchinson Cancer Center
- **Conditions:** Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- **Enrollment:** 15 participants

#### MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
- **NCT ID:** [NCT06150417](https://www.granted.bio/trial/NCT06150417)
- **Phase:** PHASE2
- **Status:** RECRUITING
- **Sponsor:** Case Comprehensive Cancer Center
- **Conditions:** Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
- **Enrollment:** 200 participants


> **61 of 500 surfaced trials terminated or stopped early** (source: statusModule.whyStopped on ClinicalTrials.gov).
>
> - **NCT04264208** (Andrei Iagaru): Lack of accrual due to pandemic and logistics
> - **NCT00619515** (Case Comprehensive Cancer Center): Prematurely terminated at institution request
> - **NCT00544778** (City of Hope Medical Center): The study was terminated prematurely due to withdrawal of support by the sponsor.
> - **NCT04995536** (City of Hope Medical Center): no accrual
> - **NCT00458549** (Dana-Farber Cancer Institute): Slow Accrual
> - *…and 56 more terminated trials in the surfaced set. See Trials for the full list.*

---

## Patent Activity

*Note: This analysis includes only patents linked to NIH-funded projects. Commercial patents and international filings may exist outside this sample. USPTO filing timelines also lag commercial activity by roughly 18-24 months, so very recent private R&D may not yet appear in patent data.*

**IP Concentration:** Highly Concentrated - Few dominant owners

**Dominant Patent Holders:** JOHNS HOPKINS UNIVERSITY, UNIVERSITY OF WASHINGTON, UNIVERSITY OF WISCONSIN-MADISON, INSTITUTE FOR SYSTEMS BIOLOGY, UNIVERSITY OF IOWA

**Recent Activity:** Within the linked sample, zero patents have been filed or linked in the past two years, suggesting either a slowdown in NIH-project-linked patenting activity or a lag in linkage indexing, though this observation cannot be extended to the broader commercial filing landscape.

**Confidence: Low** - Evidence: 0 of 29 linked patents dated within the last 2 years; with a small NIH-linked sample, the true recent filing rate across commercial assignees is not resolvable here.

### Freedom to Operate Assessment

Among the NIH-linked patents in this sample, filings cover PSMA-targeted agents, chelation chemistry, and radiolabeled inhibitor synthesis, with a single assignee holding 15 of 29 linked patents (raw count). A new entrant working in PSMA-targeted radioligand therapy would likely encounter overlapping prior art in ligand scaffold design, radiolabeling methods (including 18F and 68Ga approaches), and multivalent inhibitor architectures.

**Confidence: Medium** - Evidence: 15 patents from one assignee, 29 total NIH-linked patents across 7 assignees; commercial and international patents from industry actors are not represented in this sample and are likely to expand the FTO surface considerably beyond what is visible here.

The NIH-linked patent sample consists entirely of academic assignees, with all 29 patents attributed to universities and research institutes, and no commercial-sector patents appearing in the linked set. This composition indicates that the NIH-linked IP in PSMA-targeting chemistry, radioligand synthesis, and theranostic scaffold design was captured largely in academic settings, which typically makes licensing access more straightforward than navigating commercial exclusivities - though industry actors such as Novartis (Lutathera, Pluvicto) and others operating in this space hold separate patent portfolios not captured here.

**Confidence: Medium** - Evidence: 29 linked patents across 7 academic assignees, 0 commercial assignees visible in the NIH-linked sample; the academic-only composition of this sample is likely an artifact of NIH-project linkage scope rather than a reflection of the full commercial IP environment.

### Strategic Implications

For a researcher assessing this space, the dominant finding is that the NIH-linked foundational IP sits within academic technology transfer systems, which are typically navigable through standard licensing channels. The technical methods at highest prior-art density within this sample are PSMA-inhibitor scaffold design, radiometal chelation chemistry (NOTA, phospholipid chelates), and fluorine-18/gallium-68 radiolabeling synthesis routes - these are the areas where a claim-level prior-art review would be most informative before initiating analogous work. The absence of recent NIH-linked filings and the complete absence of commercial patents in this sample both warrant caution: the commercial landscape around approved agents and their manufacturing processes is likely substantially more complex than this sample reflects, and a researcher considering translational or collaborative work should treat this dataset as a starting orientation rather than a comprehensive FTO assessment.

**Confidence: Low** - Evidence: 29 NIH-linked patents, 0 from commercial assignees, 0 filed in the last 2 years; with an exclusively academic and small linked sample, the true commercial IP density in radioligand therapy for prostate cancer is not resolvable from this data alone.

### Patent Analysis

Among the linked patents, Johns Hopkins University accounts for 15 of 29 total linked patents, with a portfolio centered on PSMA-targeted small molecules - including urea-based scaffolds, multivalent PSMA inhibitors, radiolabeled PSMA inhibitors for endoradiotherapy, PSMA-targeted photosensitizers, and 18F-DCFPyL synthesis methods - indicating deep and layered IP protection around PSMA-directed theranostics that may reflect long-term translational investment in this target class. University of Wisconsin-Madison contributes a distinct cluster of patents around radioactive phospholipid metal chelate compounds designed for both tumor-selective retention and in situ immune modulation, suggesting a strategy of protecting the intersection of targeted radionuclide therapy and immunomodulation as a differentiated commercial direction. University of Iowa holds patents on structural optimization methods for peptide receptor-targeted radionuclide therapy chelator-ligand conjugates, pointing to translational interest in improving PRRT pharmacokinetics beyond the current standard. Notably, the sample shows zero patents filed within the past two years, which may reflect publication or disclosure lags rather than a cessation of IP activity, and the aggregate portfolio skews heavily toward PSMA-targeting and chelation chemistry rather than AI-based dosimetry or resistance-mechanism innovations - areas prominent in funded research but not yet well-represented in the examined IP.

### Patent Summary

| Metric | Value |
|--------|-------|
| Total Patents (grant-linked) | 29 |
| Unique Assignees | 7 |
| Recent (2 years) | 0 |

### Key Patents

#### Compositions and Methods for Chemical Exchange Saturation Transfer (Cest) Based Magnetic Resonance Imaging (MRI)
- **Patent #:** [10188754](https://www.granted.bio/patent/10188754)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) or frequency labeled exchange (FLEX) imaging are disclosed. Beta-hydroxycarboxylate and...

#### Prostate-specific Membrane Antigen-targeted Photosensitizers for Photodynamic Therapy
- **Patent #:** [10232058](https://www.granted.bio/patent/10232058)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> Urea-based photosensitizers, which target prostate-specific membrane antigen (PSMA) for imaging and targeted therapy of PSMA-expressing tumors and cancers are disclosed.

#### HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF
- **Patent #:** [10653806](https://www.granted.bio/patent/10653806)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthes...

#### Metal/Radiometal-Labeled PSMA Inhibitors for PSMA-Targeted Imaging and Radiotherapy
- **Patent #:** [10683272](https://www.granted.bio/patent/10683272)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhib...

#### SALICYLIC ACID-BASED POLYMERIC CEST CONTRAST AGENTS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF
- **Patent #:** [10688198](https://www.granted.bio/patent/10688198)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen, pharmaceutical composition comprising the same and methods of use thereof are disclosed.

#### 68Ga-labeled NOTA-Chelated PSMA-targeted imaging and therapeutic agents
- **Patent #:** [10717750](https://www.granted.bio/patent/10717750)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> PSMA-targeted PET/SPECT agents for imaging PSMA-positive cancer and or tumor neovasculature and PSMA-targeted radiotherapeutic agent for the treatment of PSMA-positive cancer or tumor neovasculature a...

#### New Scaffolds and Multifunctional Intermediates for Imaging PSMA
- **Patent #:** [10736974](https://www.granted.bio/patent/10736974)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or...

#### TARGETED RADIOTHERAPY CHELATES FOR IN SITU IMMUNE MODULATED CANCER VACCINATION
- **Patent #:** [10751430](https://www.granted.bio/patent/10751430)
- **Assignee:** UNIVERSITY OF WISCONSIN-MADISON

> The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound t...

#### An improved synthesis of the radiolabeled PSMA inhibitor, [18F] DCFPyL
- **Patent #:** [10947197](https://www.granted.bio/patent/10947197)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> Methods, and related compositions, for the improved synthesis of [ 18 F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [ 18 F]DCFPyL so produced.

#### RADIOACTIVE PHOSPHOLIPID METAL CHELATES FOR CANCER IMAGING AND THERAPY
- **Patent #:** [11186598](https://www.granted.bio/patent/11186598)
- **Assignee:** UNIVERSITY OF WISCONSIN-MADISON

> Alkylphosphocholine analogs incorporating a chelating moiety that chelates a radioactive metal isotope are disclosed herein. The alkylphophocholine analogs, which can be used to treat or detect solid ...

#### PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER
- **Patent #:** [11458213](https://www.granted.bio/patent/11458213)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.

#### PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER
- **Patent #:** [11478558](https://www.granted.bio/patent/11478558)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.

#### Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination
- **Patent #:** [11730834](https://www.granted.bio/patent/11730834)
- **Assignee:** UNIVERSITY OF WISCONSIN-MADISON

> The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound t...

#### PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY
- **Patent #:** [11814365](https://www.granted.bio/patent/11814365)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific me...

#### SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL
- **Patent #:** [11851407](https://www.granted.bio/patent/11851407)
- **Assignee:** JOHNS HOPKINS UNIVERSITY

> Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.



---

## Key Publications

*Note: This analysis includes only publications linked to NIH-funded projects and may not represent the complete body of literature in this field. PubMed indexing typically lags publication date by 1-3 months for peer-reviewed articles; preprints appear faster but are not peer-reviewed.*

The publication record linked to this sample - anchored by 646 total works with the Journal of Nuclear Medicine as the most frequent outlet (43 publications) - reflects a field operating across both translational radiopharmaceutical science and adjacent oncology disciplines. Key scientific questions being addressed include posttreatment imaging optimization for peptide receptor radionuclide therapy, structural modifications to Pb-203/Pb-212 peptide pairs for improved alpha-particle therapy of neuroendocrine tumors, and synthesis and preliminary evaluation of At-211-labeled PSMA inhibitors for targeted alpha therapy of prostate cancer, suggesting active bench-to-clinic translation of next-generation radionuclides. Methodological advances visible in the sample include preclinical PARP-targeted Meitner-Auger theranostic radiopharmaceuticals, pretargeted alpha therapy using bioorthogonal click chemistry for ovarian cancer, and hyperpolarized 13C MRI as a metabolic response biomarker - techniques that broaden the mechanistic toolkit available for monitoring and optimizing radiopharmaceutical therapy. The appearance of deep learning and multimodal data frameworks for treatment effect inference in the publication set, alongside classical radiochemistry and radiobiology outputs, indicates that computational and quantitative methods are increasingly intersecting with the radiopharmaceutical sciences represented in this sample.

### Must-Read Publications

#### 1. Combination Metastasis-Targeted External Beam Radiation Therapy With (177)Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer.
- **Journal:** Practical Radiation Oncology | **Year:** 2025
- **PMID:** [40274261](https://pubmed.ncbi.nlm.nih.gov/40274261)

**Why it matters:** This retrospective study directly addresses the real-world integration of metastasis-directed external beam radiation therapy (M-EBRT) with 177Lu-PSMA-617 (LuPSMA) radioligand therapy in patients with advanced castration-resistant prostate cancer. For a researcher entering this field, it provides practical clinical data on how these two modalities are combined, including timing, indications, tolerability, and PSA response - all critical for understanding current translational practice.

**Key finding:** M-EBRT was used alongside LuPSMA in 20% of patients primarily for intracranial/epidural disease and bone palliation, was well tolerated, and provided symptom relief in 62% of cases, supporting its role as an adjunct to radioligand therapy.

#### 2. Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.
- **Journal:** Molecular Cancer Research : Mcr | **Year:** 2026
- **PMID:** [42189191](https://pubmed.ncbi.nlm.nih.gov/42189191)

**Why it matters:** KLK2 and STEAP1 are emerging cell surface targets for radioligand therapy and antibody-drug conjugate approaches in prostate cancer. This integrative molecular profiling study characterizes their expression across metastatic castration-resistant prostate cancer subtypes, defines co-expression with PSMA, and maps regulatory mechanisms - directly informing target selection and patient stratification for next-generation radioligand therapy trials.

**Key finding:** KLK2 and STEAP1 are co-expressed with PSMA in androgen receptor-positive metastatic castration-resistant prostate cancer, with high combined positivity rates suggesting that cotargeting any two of these antigens increases overall tumor coverage.

### Publication Summary

- Total linked publications: 646
- Unique journals: 249
- Publications with year metadata: 645 (the remaining 1 have no parsable year on the PubMed record and are not shown in the year distribution below)

**Top Journals:**

- Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine (43)
- bioRxiv : the Preprint Server for Biology (32)
- Clinical Cancer Research : an Official Journal of the American Association for Cancer Research (18)
- Cancers (17)
- International Journal of Radiation Oncology, Biology, Physics (14)



---

## Key Organizations

*Top 15 of 52 funded organizations, ranked by NIH funding within the analyzed sample.*

| Organization | Projects | Funding | Pubs (grant-linked) | Trials (grant-linked) | Patents (grant-linked) |
|--------------|----------|---------|--------------------|-----------------------|------------------------|
| [University of California, San Francisco](https://www.granted.bio/org/UNIVERSITY%20OF%20CALIFORNIA%2C%20SAN%20FRANCISCO) | 11 | $12.5M | 82 | 5 | 0 |
| [Sloan-Kettering Inst Can Research](https://www.granted.bio/org/SLOAN-KETTERING%20INST%20CAN%20RESEARCH) | 10 | $8.1M | 44 | 0 | 0 |
| [University of Wisconsin-Madison](https://www.granted.bio/org/UNIVERSITY%20OF%20WISCONSIN-MADISON) | 8 | $4.6M | 128 | 4 | 3 |
| [Division of Basic Sciences - Nci](https://www.granted.bio/org/DIVISION%20OF%20BASIC%20SCIENCES%20-%20NCI) | 7 | $12.4M | 0 | 1 | 0 |
| [Johns Hopkins University](https://www.granted.bio/org/JOHNS%20HOPKINS%20UNIVERSITY) | 6 | $9.0M | 33 | 2 | 0 |
| [Washington University](https://www.granted.bio/org/WASHINGTON%20UNIVERSITY) | 5 | $4.1M | 1 | 1 | 0 |
| [Case Western Reserve University](https://www.granted.bio/org/CASE%20WESTERN%20RESERVE%20UNIVERSITY) | 5 | $2.8M | 7 | 1 | 0 |
| [Beckman Research Institute/City of Hope](https://www.granted.bio/org/BECKMAN%20RESEARCH%20INSTITUTE%2FCITY%20OF%20HOPE) | 3 | $3.4M | 8 | 1 | 0 |
| [University of Pittsburgh at Pittsburgh](https://www.granted.bio/org/UNIVERSITY%20OF%20PITTSBURGH%20AT%20PITTSBURGH) | 3 | $2.5M | 7 | 0 | 0 |
| [University of California Los Angeles](https://www.granted.bio/org/UNIVERSITY%20OF%20CALIFORNIA%20LOS%20ANGELES) | 3 | $2.3M | 8 | 1 | 0 |
| [Fred Hutchinson Cancer Center](https://www.granted.bio/org/FRED%20HUTCHINSON%20CANCER%20CENTER) | 3 | $2.1M | 90 | 14 | 9 |
| [Ut Southwestern Medical Center](https://www.granted.bio/org/UT%20SOUTHWESTERN%20MEDICAL%20CENTER) | 2 | $4.2M | 51 | 0 | 15 |
| [Stanford University](https://www.granted.bio/org/STANFORD%20UNIVERSITY) | 2 | $3.0M | 4 | 0 | 0 |
| [University of Virginia](https://www.granted.bio/org/UNIVERSITY%20OF%20VIRGINIA) | 2 | $2.0M | 1 | 0 | 0 |
| [Icahn School of Medicine at Mount Sinai](https://www.granted.bio/org/ICAHN%20SCHOOL%20OF%20MEDICINE%20AT%20MOUNT%20SINAI) | 2 | $1.8M | 7 | 0 | 0 |

*Trials, patents, and publications counted here are those where an NIH grant belonging to this org was acknowledged. Patent assignee, trial sponsor, and publication first-author affiliation may differ from the org named on the underlying NIH grant. See the Patent Activity section for a separate view by assignee.*


---

## Key Researchers

| Researcher | Projects | Funding | Organization |
|------------|----------|---------|-------------|
| [CHOYKE, PETER L (contact)](https://www.granted.bio/researcher/CHOYKE%2C%20PETER%20L%20(contact)) | 2 | $5.8M | Division of Basic Sciences - Nci |
| [KIESS, ANA PONCE](https://www.granted.bio/researcher/KIESS%2C%20ANA%20PONCE) | 1 | $5.7M | Johns Hopkins University |
| [CITRIN, DEBORAH  (contact)](https://www.granted.bio/researcher/CITRIN%2C%20DEBORAH%20%20(contact)) | 1 | $3.6M | Division of Basic Sciences - Nci |
| [VIGNERON, DANIEL B](https://www.granted.bio/researcher/VIGNERON%2C%20DANIEL%20B) | 2 | $2.6M | University of California, San Francisco |
| [LANGTON-WEBSTER, BEATRICE](https://www.granted.bio/researcher/LANGTON-WEBSTER%2C%20BEATRICE) | 1 | $2.4M | Cancer Targeted Technology, LLC |
| [MCNEEL, DOUGLAS G. (contact)](https://www.granted.bio/researcher/MCNEEL%2C%20DOUGLAS%20G.%20(contact)) | 1 | $2.4M | University of Wisconsin-Madison |
| [NGAMCHERDTRAKUL, WORAPOL](https://www.granted.bio/researcher/NGAMCHERDTRAKUL%2C%20WORAPOL) | 1 | $2.2M | Pdx Pharmaceuticals, Inc. |
| [EVANS, MICHAEL JOHN](https://www.granted.bio/researcher/EVANS%2C%20MICHAEL%20JOHN) | 2 | $2.0M | University of California, San Francisco |
| [MAHER, CHRISTOPHER A](https://www.granted.bio/researcher/MAHER%2C%20CHRISTOPHER%20A) | 1 | $1.8M | Washington University |
| [BASILION, JAMES PETER](https://www.granted.bio/researcher/BASILION%2C%20JAMES%20PETER) | 2 | $1.8M | Case Western Reserve University |
| [POMPER, MARTIN G](https://www.granted.bio/researcher/POMPER%2C%20MARTIN%20G) | 2 | $1.7M | Ut Southwestern Medical Center |
| [RAO, JIANGHONG](https://www.granted.bio/researcher/RAO%2C%20JIANGHONG) | 1 | $1.7M | Stanford University |
| [SCHWARTZ, LAWRENCE H](https://www.granted.bio/researcher/SCHWARTZ%2C%20LAWRENCE%20H) | 1 | $1.7M | Sloan-Kettering Inst Can Research |
| [MOORE, JARED WILLIAM](https://www.granted.bio/researcher/MOORE%2C%20JARED%20WILLIAM) | 1 | $1.6M | Qscint Imaging Solutions, LLC |
| [PONOMAREV, VLADIMIR](https://www.granted.bio/researcher/PONOMAREV%2C%20VLADIMIR) | 1 | $1.4M | Sloan-Kettering Inst Can Research |


---

## Next Steps

*Concrete actions the report suggests based on what's above. Not exhaustive - use these as a starting checklist you can extend.*

- **Investigate the mCRPC white-space signal before building a proposal around it.** The Coverage Gap Signals section flags Metastatic Castration-Resistant Prostate Cancer (mCRPC) as underrepresented in the analyzed sample (sample = 0) relative to the broader NIH portfolio (n = 65). Before treating this as a clean opportunity, run a NIH RePORTER keyword search combining "radioligand therapy" or "PSMA" with "castration-resistant" to determine whether the gap reflects real whitespace or a terminology artifact - funding may exist under adjacent labels such as "CRPC," "AR-independent," or "enzalutamide-resistant." Draft an R21 or R01 specifically addressing mCRPC only if the gap holds up after that cross-check.

- **Audit the IP landscape independently before drawing conclusions from the 29-patent count.** The report's patent sample is gated to NIH-acknowledged filings, which structurally excludes commercial-only, international, and continuation filings. The "highly concentrated" IP concentration flag (see the IP and Patents section) is a directional signal, not a complete picture. Run parallel searches on USPTO, Google Patents, and PATENTSCOPE using assignee filters for radioligand, PSMA, and alpha/beta emitter terms to build a full assignee map before making any IP-informed proposal or licensing decisions.

- **Map your methodological positioning against the funded project cluster.** With 115 projects across 52 organizations, the sample is large enough to reveal methodological clustering. Review the Key Research Projects table and filter by your primary approach (e.g., dosimetry optimization, combination regimens, novel isotope conjugation) to assess how saturated your specific angle is and where refinement or differentiation is needed before submission.

- **Review the concentration of funding around the top five PIs as a benchmark for proposal scope.** The top five PIs collectively hold 7 projects (see the Key Researchers table). Read the funded abstracts and grant titles associated with projects in your methodological category - available via NIH RePORTER - to understand the scope, specific aims framing, and mechanism choices that have been funded, and use that as a calibration point for your own proposal structure.

- **Assess whether an R21 or U01 mechanism fits an underexplored combination or delivery angle.** The $105.9M total funding base and 500-trial sample suggest substantial R01-level activity in core radioligand mechanisms. If your research addresses a translational gap - such as patient selection biomarkers, dosimetry modeling for novel isotopes, or radioligand-immunotherapy combinations - check NIH program announcements for R21 (exploratory/developmental) or U01 (cooperative agreement) mechanisms, which may be better fits for earlier-stage or multi-site work than a standard R01.

- **Use the Key Organizations table to map which institutions are active in your specific methodological category before writing the Significance and Innovation sections.** Knowing the concentration of activity by approach (e.g., alpha-emitter vs. beta-emitter, theranostic pairing, linker chemistry) will help you accurately characterize the state of the field, avoid overclaiming novelty in areas with dense existing funding, and correctly position your contribution relative to the existing portfolio.

- **Cross-check the 500-trial count against ClinicalTrials.gov directly to identify stage distribution gaps.** The trial sample reflects only NIH-acknowledged registrations. Run a ClinicalTrials.gov search filtered by "radioligand" and "prostate" to assess the full Phase I/II/III distribution and identify whether early-phase mechanistic trials or late-phase comparative effectiveness trials are underrepresented - this will sharpen the translational framing of any proposal targeting a specific development stage.

- **Evaluate SBIR/STTR applicability if your work involves a novel radiopharmaceutical component, but verify the gap first.** The mCRPC signal and the broader funding pattern suggest possible commercial development angles, particularly around delivery vehicles or diagnostic pairing agents. Before drafting an SBIR Phase I, confirm via RePORTER and the NIH Small Business portal that the specific technical problem you are addressing is not already carried by an active SBIR award - the 52-organization spread means some whitespace may already be covered by small-business mechanisms not prominently visible in the academic-PI-focused sections of this report.

---

## About This Report

### Methodology

This report analyzes a curated subset of NIH-funded research projects most relevant to **radioligand therapy for prostate cancer**. Projects were identified using semantic search (AI-based conceptual matching) and filtered by match quality.

**Search Interpretation Used:** Standard - "radioligand therapy and targeted radionuclide therapy for prostate cancer treatment"

**Note on Funding Figures:** Per-project funding amounts shown in this report are the sum of award totals across all budget periods for each project (not just the most recent year). Funding-by-year figures show actual spend per fiscal year drawn from the underlying NIH RePORTER budget-period rows, so a multi-year project contributes to each year it received funding. The current NIH fiscal year (Oct 1 - Sep 30) is partial when this report is generated; that year is labeled "(YTD)" in tables and charts and should not be compared directly to fully-reported prior years.

**Note on Funding Attribution:** Clinical trials are surfaced through two paths - direct linkage to topically-relevant projects, *and* semantic similarity between the trial's own title and the topic (using the same vector-embedding mechanism that powers project search, gated by a dedicated trial-inclusion threshold). The second path catches trials that sit under broad institutional umbrella awards (e.g., P30 cancer center support grants, CTSA hubs) whose underlying parent grant covers many unrelated programs. Those trials are reported because their titles are clearly about the topic, but their umbrella grants' funding is *not* rolled into Total Committed Funding - only projects whose own abstracts clear the project-relevance threshold contribute to funding totals. This keeps the headline funding number topically attributable rather than inflated by institutional overhead grants that happen to host one relevant program among many.

**Match Quality Tiers:**

| Tier | Similarity | Description |
|------|------------|-------------|
| **Precise** | ≥50% | Highly relevant - directly addresses the topic |
| **Balanced** | ≥35% | Relevant - related research with clear connection |

**Sample Composition:**

| Metric | Value |
|--------|-------|
| Projects Analyzed | 115 |
| Precise Matches | 115 |
| Balanced Matches | 0 |
| Total Committed Funding | $105.9M |
| Organizations | 52 |
| Principal Investigators | 125 |

**Sample Interpretation:**

- **All 115 matches are Precise** (similarity ≥50%). This is not a tuned threshold - it reflects the topic mapping to a tightly-bounded research area where most relevant NIH grants land above the 50% similarity cutoff. Broader topics with less coherent literature produce mixed Precise + Balanced splits (typically 60/40 to 80/20). Note that "Precise" measures semantic similarity to the query, not perfect topical fit - a project can score above the threshold and still touch adjacent research areas (e.g., a project whose main focus is diagnostic biomarkers but whose abstract mentions sepsis biomarkers as comparator work). Treat this signal as "the field's vocabulary aligns well with our query," not as "every project is a pure topic match."



**Linked Data:**

| Data Type | Count | Source |
|-----------|-------|--------|
| Clinical Trials | 500 | ClinicalTrials.gov |
| Patents | 29 | USPTO |
| Publications | 646 | PubMed |

### Limitations

This analysis focuses on **depth over breadth**, capturing publicly-funded academic research. It does not include privately-funded industry R&D or international research outside NIH grants.

*Data current as of September 21, 2026.*

---

*Analysis generated by granted.bio. Browse more analyses or generate your own: https://www.granted.bio*
